Patricia Troncoso, MD

Peer-Reviewed Articles

1. Mak, SL, Zhu, M, Fu, J, Liang, X, Wang, X, Yuan, F, Wang, F, Hoang, A, Song, X, Shepherd, P, Liang, D, Suh, J, Contreras, J, Dang, T, Yan, C, Figueroa, B, Mazzocco, M, Luo, A, Pradhan, B, Park, J, Bashir, M, Zhang, M, Metzger, E, Schüle, R, Jain, A, Karasik, E, Frigo, DE, Foster, BA, Lee, MG, Corn, P, Logothetis, CJ, Aparicio, A, Navone, NM, Troncoso, P, Tan, Z, Zhang, J, Lin, S, Wang, G. KDM4A promotes NEPC progression through regulation of MYC expression. Cancer Letters 638, 2026. e-Pub 2026. PMID: 41319861.
2. Sherry, AD, Siddiqui, BA, Haymaker, CL, Fellman, B, Medina-Rosales, M, Bathala, TK, Wang, S, Liu, S, Seo, A, Kobayashi, K, Lu, H, Troncoso, P, Chun, SG, Ha, CS, Mayo, LL, Mok, H, Park, RJ, Chapin, BF, Phillips, RM, Deek, MP, Kovitz, CA, Aparicio, A, Zurita-Saavedra, A, Pilie, PG, Cohen, L, Choi, S, Reuben, A, Tran, PT, Corn, P, Subudhi, SK, Tang, C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer. European urology 88(5):496-509, 2025. e-Pub 2025. PMID: 40750497.
3. Zurita-Saavedra, A, Tidwell, R, Chapin, BF, Harris, DR, Zhang, M, Pisters, LL, Aparicio, A, Araujo, JC, Arce-Gallego, S, Zhu, K, Lozano, ML, Pagliaro, LC, Mateo, J, Logothetis, CJ, Troncoso, P, Davis, JW. Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. European Urology Oncology 8(4):1010-1019, 2025. e-Pub 2025. PMID: 40651932.
4. Nourbakshs M, Du L, Acosta AM, Alaghehbandan R, Amin A, Amin MB, Aron M, Berney D, Brimo F, Chan E, Cheng L, Colecchia M, Dhillon J, Downes MR, Evans AJ, Harik LR, Hassan O, Haider A, Humphrey PA, Jha S, Kandukuri S, Kao CS, Kaushal S, Khani F, Kryvenko ON, Kweldam C, Lal P, Lobo A, Maclean F, Magi-Galluzzi C, Mehra R, Miyamoto H, Mohanty SK, Montironi R, Nesi G, Netto GJ, Nguyen JK, Nourieh M, Osunkoya AO, Paner GP, Sangoi AR, Shah RB, Srigley JR, Tretiakova M, Troncoso P, Trpkov K, Van Der Kwast TH, Zhang M, Zynger DL, Williamson SR, Giannico GA. Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists. Histopathology 87(2):206-222, 2025. e-Pub 2025. PMID: 40364451.
5. Hassanzadeh, CJ, Kuban, DA, Pasyar, S, Bassett Jr, R, Troncoso, P, Ansari, M, Schlembach, PJ, McGuire, SE, Nguyen, Q, Frank, SJ, Mok, H, Mohamad, O, Park, RJ, Tang, C, Du, W, Kudchadker, RJ, Choi, S, Hoffman, K. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer. Journal of Clinical Oncology 43(18):2044-2048, 2025. e-Pub 2025. PMID: 40367400.
6. Zhao, Y, Ramesh, N, Xu, P, Sei, E, Hu, M, Bai, S, Troncoso, P, Aparicio, A, Logothetis, CJ, Corn, P, Navin, N, Zurita-Saavedra, A. Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy. Cancer Research 85(9):1680-1695, 2025. e-Pub 2025. PMID: 39992716.
7. Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Chery L, Urkmez A, Fang AM, Higgason N, Troncoso P, Daniel CR, Logothetis C, Thompson TC, Hahn AW, Liu M, Zheng Y, Lin DW, Hanash S, Irajizad E, Fahrmann J. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res 12(1):134, 2024. e-Pub 2024. PMID: 39522029.
8. Hahn, AW, Manyam, GC, Chapin, BF, Zhang, M, Yu, Y, Pettaway, CA, Chery, LJ, Pisters, LL, Ward, JF, Gregg, JR, Papadopoulos, JN, Kamat, A, Lozano, M, Hoang, A, Broom, BM, Wang, X, Huff, C, Logothetis, CJ, Troncoso, P, Pilie, PG, Davis, JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU international 134(3):449-458, 2024. e-Pub 2024. PMID: 38837608.
9. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A 121(33):e2402903121, 2024. e-Pub 2024. PMID: 39102549.
10. Aparicio, A, Tidwell, RS, Yadav, SS, Chen, JS, Zhang, M, Liu, J, Guo, S, Pilie, PG, Yu, Y, Song, X, Vundavilli, H, Jindal, S, Zhu, K, Viscuse, PV, Lebenthal, J, Hahn, AW, Soundararajan, R, Corn, P, Zurita-Saavedra, A, Subudhi, SK, Zhang, J, Wang, W, Huff, C, Troncoso, P, Allison, JP, Sharma, P, Logothetis, CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
11. Anselmino, N, Labanca, E, Shepherd, P, Dong, J, Yang, J, Song, X, Nandakumar, S, Kundra, R, Lee, CJ, Schultz, N, Zhang, J, Araujo, JC, Aparicio, A, Subudhi, SK, Corn, P, Pisters, LL, Ward, JF, Davis, JW, Vazquez, ES, Gueron, G, Logothetis, CJ, Futreal, A, Troncoso, P, Chen, Y, Navone, NM. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clinical Cancer Research 30(10):2272-2285, 2024. e-Pub 2024. PMID: 38488813.
12. Gu, J, Chery, LJ, González, GM, Huff, C, Strom, SS, Jones, J, Griffith, DP, Canfield, SE, Wang, X, Huang, X, Roberson, P, Meng, QH, Troncoso, P, Ittmann, MM, Covinsky, MH, Scheurer, ME, Irizarry-Ramírez, M, Pettaway, CA. A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate 84(7):694-705, 2024. e-Pub 2024. PMID: 38477020.
13. Gregg, JR, Magill, RG, Fang, AM, Chapin, BF, Davis, JW, Adibi, M, Chery, LJ, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Ward, J, Hahn, AW, Daniel-MacDougall, CR, Bhaskaran, J, Zhu, K, Guerrero, M, Zhang, M, Troncoso, P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
14. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment. bioRxiv, 2023. e-Pub 2023. PMID: 38076845.
15. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
16. Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. e-Pub 2022. PMID: 36100698.
17. Ranasinghe WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TK. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology 303(1):204732, 2022. e-Pub 2022. PMID: 35076303.
18. Labanca E, Yang J, Shepherd PDA, Wan X, Starbuck MW, Guerra LD, Anselmino N, Bizzotto JA, Dong J, Chinnaiyan AM, Ravoori MK, Kundra V, Broom BM, Corn PG, Troncoso P, Gueron G, Logothethis CJ, Navone NM. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Eur Urol Oncol 5(2):164-175, 2022. e-Pub 2022. PMID: 34774481.
19. Sen A, Troncoso P, Venkatesan A, Pagel MD, Nijkamp JA, He Y, Lesage AC, Woodland M, Brock KK. Correlation of in-vivo imaging with histopathology: A review. Eur J Radiol 144:109964, 2021. e-Pub 2021. PMID: 34619617.
20. Wu C, Peng S, Pilié PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. Mol Cancer Ther 20(9):1680-1691, 2021. e-Pub 2021. PMID: 34158347.
21. Grypari IM, Logotheti S, Zolota V, Troncoso P, Efstathiou E, Bravou V, Melachrinou M, Logothetis C, Tzelepi V. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (Baltimore) 100(36):e27094, 2021. e-Pub 2021. PMID: 34516499.
22. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
23. Urkmez A, Ward JF, Choi H, Troncoso P, Inguillo I, Gregg JR, Altok M, Demirel HC, Qiao W, Kang HC. Temporal Learning Curve of a Multidisciplinary Team for MRI-TRUS Fusion Prostate Biopsy. BJU Int 127(5):524-527, 2021. e-Pub 2021. PMID: 33340435.
24. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol 79(2):298-306, 2021. e-Pub 2021. PMID: 33279304.
25. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2021. PMID: 32675015.
26. Shah RB, Cai Q, Aron M, Berney DM, Cheville JC, Deng FM, Epstein J, Fine SW, Genega EM, Hirsch MS, Humphrey PA, Gordetsky J, Kristiansen G, Kunju LP, Magi-Galluzzi C, Gupta N, Netto GJ, Osunkoya AO, Robinson BD, Trpkov K, True LD, Troncoso P, Varma M, Wheeler T, Williamson SR, Wu A, Zhou M. Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res 11(8):3990-4001, 2021. e-Pub 2021. PMID: 34522463.
27. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin Cancer Res 26(18):4933-4946, 2020. e-Pub 2020. PMID: 32576626.
28. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126(16):3667-3673, 2020. e-Pub 2020. PMID: 32453443.
29. Ramesh N, Sei E, Tsai PC, Bai S, Zhao Y, Troncoso P, Corn PG, Logothetis C, Zurita AJ, Navin NE. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol 21(1):162, 2020. e-Pub 2020. PMID: 32631448.
30. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
31. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically-Based Factors Associated with Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology 138:91-97, 2020. e-Pub 2020. PMID: 31899230.
32. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75, 2020. e-Pub 2020. PMID: 31986451.
33. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
34. Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis 23(1):172-178, 2020. e-Pub 2020. PMID: 31501508.
35. Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, Hoang A, Perimenis P, Melachrinou M, Logothetis C, Zolota V. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology 52(2):218-227, 2020. e-Pub 2020. PMID: 31864524.
36. Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol 3(1):119-127, 2020. e-Pub 2020. PMID: 31412017.
37. Altok M, Troncoso P, Achim MF, Matin SF, Gonzalez GN, Davis JW. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates. Asian J Androl 21(6):598-604, 2019. e-Pub 2019. PMID: 31115364.
38. Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res 25(22):6839-6851, 2019. e-Pub 2019. PMID: 31439587.
39. Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol 76(4):418-424, 2019. e-Pub 2019. PMID: 31176622.
40. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
41. Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, Kim J. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nat Rev Clin Oncol 16(3):168-184, 2019. e-Pub 2019. PMID: 30413793.
42. Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol 21(1):86-94, 2019. e-Pub 2019. PMID: 29748904.
43. Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF. Detection and Treatment of Primary Prostatic Melanoma. Urology 123:16-19, 2019. e-Pub 2019. PMID: 30195014.
44. Korkut, A, Kanchi, RS, Li, X, Lorenzi, PL, Kwong, L, Roszik, J, Ling, S, Uppore Kukkillaya, AR, Liu, Y, Ju, Z, Hansel, DE, Li, S, Ajani, JA, Mani, S, Chen, J, Ma, W, Zhang, J, Broom, BM, Li, J, Liang, H, Liu, W, Lu, Y, Mills, GB, Weinstein, JN, Liu, X, Wang, L, Carvalho, AL, Fregnani, JG, Reis, RV, Scapulatempo, CN, Behrens, MC, Bondaruk, J, Broaddus, R, Czerniak, BA, Esmaeli, B, Fujimoto, J, Gershenwald, JE, Guo, CC, Lazar, A, Logothetis, CJ, Meric-Bernstam, F, Moran, C, Ramondetta, LM, Rice, DC, Sood, AK, Tamboli, P, Thompson, T, Troncoso, P, Tsao, A, Wistuba, II, von Deimling, A, Mishra, L, Akbani, R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
45. Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM, Troncoso P, DePinho RA, Wang YA. An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer. Cancer Res 78(14):3823-3833, 2018. e-Pub 2018. PMID: 29769196.
46. Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW. Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection. BJU Int 122(1):66-75, 2018. e-Pub 2018. PMID: 29446205.
47. Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol 74(1):107-114, 2018. e-Pub 2018. PMID: 29233664.
48. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, EMLN T, Davis JW, Troncoso P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis 21(1):221-227, 2018. e-Pub 2018. PMID: 29230008.
49. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2018. PMID: 29138344.
50. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys 100(2):374-382, 2018. e-Pub 2018. PMID: 29229325.
51. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer. BJU Int 121(1):69-76, 2018. e-Pub 2018. PMID: 28710901.
52. Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-Grade Neuroendocrine Carcinoma of the Urachus - Report of 3 Cases. Hum Pathol 67:126-133, 2017. e-Pub 2017. PMID: 28823575.
53. Metcalfe MJ, Troncoso P, Guo CC, Chen HC, Bozkurt Y, Ward JF, Pisters LL. Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes. Can Urol Assoc J 11(7):E277-E284, 2017. e-Pub 2017. PMID: 28761588.
54. Irizarry-Ramírez M, Kittles RA, Wang X, Salgado-Montilla J, Nogueras-González GM, Sánchez-Ortiz R, Guerrios L, Rivera K, Shah E, Prokhorova I, Roberson P, Troncoso P, Pettaway CA. Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men. Prostate 77(10):1118-1127, 2017. e-Pub 2017. PMID: 28543179.
55. Gilani S, Guo CC, Li-Ning EM, Pettaway C, Troncoso P. Transformation of prostatic adenocarcinoma to well differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol 64:186-190, 2017. e-Pub 2017. PMID: 28159676.
56. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 10(480), 2017. e-Pub 2017. PMID: 28536297.
57. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
58. Carlsson A, Kuhn P, Luttgen MS, Dizon KK, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis CJ, Zurita AJ. Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters. Clin Cancer Res 23(7):1722-1732, 2017. e-Pub 2017. PMID: 27702818.
59. Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543(7647):728-732, 2017. e-Pub 2017. PMID: 28321130.
60. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18(8):1970-1981, 2017. e-Pub 2017. PMID: 28228262.
61. Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542(7642):484-488, 2017. e-Pub 2017. PMID: 28166537.
62. Ferrara F, Staquicini DI, Driessen WH, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. e-Pub 2016. PMID: 27791181.
63. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2016. PMID: 26059275.
64. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget 7(29):46321-46334, 2016. e-Pub 2016. PMID: 27331874.
65. Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674, 2016. e-Pub 2016. PMID: 27241286.
66. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine 7:85-93, 2016. e-Pub 2016. PMID: 27322462.
67. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2016. PMID: 26546618.
68. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov 6(1):80-95, 2016. e-Pub 2016. PMID: 26701088.
69. Cancer Genome Atlas Research Network. Electronic address: schultz@cbio.mskcc.org. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163(4):1011-25, 2015. e-Pub 2015. PMID: 26544944.
70. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. e-Pub 2015. PMID: 26492179.
71. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis 18(3):276-80, 2015. e-Pub 2015. PMID: 26171883.
72. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A 112(27):8403-8, 2015. e-Pub 2015. PMID: 26080435.
73. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. Cancer 121(14):2411-21, 2015. e-Pub 2015. PMID: 25832466.
74. Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget 6(12):10175-94, 2015. e-Pub 2015. PMID: 25868388.
75. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. Clin Cancer Res 21(6):1273-80, 2015. e-Pub 2015. PMID: 25320358.
76. Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A 112(8):2515-20, 2015. e-Pub 2015. PMID: 25675522.
77. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. Eur Urol 67(1):53-60, 2015. e-Pub 2015. PMID: 24882673.
78. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense Androgen Deprivation Therapy with Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. J Clin Oncol 32(33):3705-3718, 2014. e-Pub 2014. PMID: 25311217.
79. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med 6(252):252ra122, 2014. e-Pub 2014. PMID: 25186177.
80. Choi H, Underwood M, Boonsirikamchai P, Matin S, Troncoso P, Ma J. Technical challenges in 3 T magnetic resonance spectroscopic imaging of the prostate - A single-institution experience. Quant Imaging Med Surg 4(4):251-258, 2014. e-Pub 2014. PMID: 25202660.
81. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. Proposed Morphologic Classification of Prostate Cancer with Neuroendocrine Differentiation. Am J Surg Pathol 38(6):756-67, 2014. e-Pub 2014. PMID: 24705311.
82. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
83. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
84. Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 7(3):484-96, 2013. e-Pub 2013. PMID: 23333597.
85. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73(2):153-61, 2013. e-Pub 2013. PMID: 22753310.
86. Andino L, Davis JW, Wei W, Prokhorova I, Troncoso P, Matin SF. Correlation of Histomorphologic Findings and Partial Neurovascular Bundle Preservation During Laparoscopic and Robotic Radical Prostatectomy. J Robotic Surg 7(1):1-8, 2013. e-Pub 2013.
87. Fisher CM, Troncoso P, Swanson DA, Munsell MF, Kuban DA, Lee AK, Yeh SF, Frank SJ. Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy 11(6):429-34, 2012. e-Pub 2012. PMID: 22727472.
88. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol 41(4):1495-503, 2012. e-Pub 2012. PMID: 22895552.
89. Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, Prokhorova IN, Troncoso P. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol 188(1):98-102, 2012. e-Pub 2012. PMID: 22578724.
90. Guo CC, Wang Y, Xiao L, Troncoso P, Czerniak BA. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol 43(5):644-9, 2012. e-Pub 2012. PMID: 21937078.
91. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Navone N, Troncoso P, Zhang W. Integrative molecular profiling reveals Asparagine Synthetase is a target in castration resistant prostate cancer. Am J Pathol 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
92. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone. J Clin Oncol 30(6):637-43, 2012. e-Pub 2012. PMID: 22184395.
93. Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10(2):218-29, 2012. e-Pub 2012. PMID: 22144662.
94. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 18(3):666-77, 2012. e-Pub 2012. PMID: 22156612.
95. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18(3):726-36, 2012. e-Pub 2012. PMID: 22298898.
96. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One 7(2):e31259, 2012. e-Pub 2012. PMID: 22363599.
97. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. GLIPR1 suppresses prostate cancer development by targeted oncoprotein destruction. Cancer Res 71(24):7694-704, 2011. e-Pub 2011. PMID: 22025562.
98. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med 3(111):111-121, 2011. e-Pub 2011. PMID: 22133722.
99. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 2011. e-Pub 2011. PMID: 22049339.
100. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 2011. e-Pub 2011. PMID: 21456067.
101. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology 58(7):1037-47, 2011. e-Pub 2011. PMID: 21707705.
102. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574-81, 2011. e-Pub 2011. PMID: 21606419.
103. Van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B, ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 24(1):16-25, 2011. e-Pub 2011. PMID: 20818340.
104. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA, ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 24(1):26-38, 2011. e-Pub 2011. PMID: 20802467.
105. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR, ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol 24(1):39-47, 2011. e-Pub 2011. PMID: 20818343.
106. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 2011. e-Pub 2011. PMID: 21040948.
107. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI, ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol 24(1):48-57, 2011. e-Pub 2011. PMID: 20729812.
108. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L, ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 24(1):6-15, 2011. e-Pub 2011. PMID: 20834234.
109. Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P. Are There Differences in Zonal Distribution and Tumor Volume of Prostate Cancer in patients with a Positive Family History?. Int Braz J Urol 36(5):571-82, 2010. e-Pub 2010. PMID: 21044374.
110. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification. Eur Urol 57(6):1030-8, 2010. e-Pub 2010. PMID: 19853370.
111. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended core biopsies: an analysis of volume and zonal distribution of tumor foci. BJU Int 105(10):1386-91, 2010. e-Pub 2010. PMID: 19888979.
112. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clin Cancer Res 16(10):2861-71, 2010. e-Pub 2010. PMID: 20460488.
113. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing Genes Associated with Prostate Cancer Development. BMC Cancer 10(1):599, 2010. e-Pub 2010. PMID: 21044312.
114. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 104(4):490-497, 2009. e-Pub 2009. PMID: 19220260.
115. GuoCC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 22(7):866-871, 2009. e-Pub 2009. PMID: 19396154.
116. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11. e-Pub 2009. PMID: 19581923.
117. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy with versus without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Cancer. Eur Urol 55(5):1135-1143, 2009. e-Pub 2009. PMID: 18783876.
118. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. e-Pub 2009. PMID: 19244175.
119. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
120. Guo CC, Pisters LL, Troncoso P. Prostate Cancer Invading the Rectum: A Clinicopathological Study of 18 Cases. Pathology 41(6):539-543, 2009. e-Pub 2009. PMID: 19900102.
121. Nakanishi H, Troncoso P, Babaian RJ. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater. J Urol 180(6):2441-5; discussion 2445-6. e-Pub 2008. PMID: 18930495.
122. Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate 68(13):1467-76, 2008. e-Pub 2008. PMID: 18618693.
123. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92. e-Pub 2008. PMID: 18818309.
124. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 2008. e-Pub 2008. PMID: 18618013.
125. McDonnell TJ, Chari NS, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 1(1):1-9, 2008. e-Pub 2008. PMID: 18237448.
126. Spiess PE, Busby JE, Jordan JJ, Steinberg JR, Bassett RL, Davuluri R, Burt K, Troncoso P, Lee AK, Taylor SH, and Pisters LL. Can Digital Rectal Examination or Transrectal Ultrasonography Biopsy Findings Predict the Side of Nodal Metastasis in Prostate Cancer?. Urol Oncol 26(1):25-30, 2008. e-Pub 2008.
127. Ochiai A, Troncoso P, Babaian RJ. Comparison of Cancers Detected at Only s Sextant or Alternative Location. BJU Int 101(7):837-840, 2008. e-Pub 2008.
128. Ochiai A, Sotelo T, Troncoso P, Bhadkamkar V, and Babaian RJ. Natural History of Biochemical Progression after Radical Prostatectomy Based on Length of a Positive Margin. Urology 71(2):308-312, 2008. e-Pub 2008.
129. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, and Babaian RJ. PCA3 Molecular Urine Assay Correlates with Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance. J Urol 179(5):1658-1659, 2008. e-Pub 2008.
130. Ochiai A, Troncoso P, Babaian RJ. The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J Urol 177(3):903-6, 2007. e-Pub 2007. PMID: 17296372.
131. Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome?. BJU Int 99(2):321-5, 2007. e-Pub 2007. PMID: 17155975.
132. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4):1224-31, 2007. e-Pub 2007. PMID: 17317833.
133. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncoso P, Pettaway CA. A Randomized Prospective Trial Evaluating Testosterone, Haemaglobin Kinetics and Quality of Life, During and After 12 Months of Androgen Deprivation After Prostatectomy; Results from the Postoperative Adjuvant Androgen Deprivation Trial. BJU Int 100(1):63-69, 2007. e-Pub 2007.
134. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. Clin Cancer Res 13(19):5816-5824, 2007. e-Pub 2007.
135. Nakanishi H, Wang X, Ochiai A, Trpkov K, Yilmaz A, Donnelly JB, Davis JW, Troncoso P, Babaian RJ. A Nomogram for Predicting Low-Volume/Low-Grade Prostate Cancer: A Tool in Selecting Patients for Active Surveillance. Cancer 110(11):2441-2447, 2007. e-Pub 2007.
136. Kassouf W, Nakanishi H, Ochiai A, Babaian KN, Troncoso P, and Babaian RJ. Effect of Prostate Volume on Tumor Grade in Patients Undergoing Radical Prostatectomy in the Era of Extended Prostatic Biopsies. J Urol 178(1):111-114, 2007. e-Pub 2007.
137. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 30(10):1281-91, 2006. e-Pub 2006. PMID: 17001160.
138. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107(1):75-82, 2006. e-Pub 2006. PMID: 16736511.
139. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanchez-Ortiz RJ, Pisters LL. Biochemical Disease-Free Survival in Men Younger than 60 Years with Prostate Cancer Treated with Radical Prostatectomy. Urology 67(4):769-773, 2006. e-Pub 2006.
140. Mathew P, Vakar-Lopez F, Troncoso P. Protracted Remission of Metastatic Epithelioid Angiosarcoma with Weekly Infusion of Doxorubicin, Paclitaxel and Cisplatin. Lancet Oncol 7(1):92-93, 2006. e-Pub 2006.
141. Kuo MT, Wei Y, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, and Savaraj N. Association of Fragile Site-Associated (FSA) Gene Expression with Epithelial Differentiation and Tumor Development. Biochem Biophys Res Commun 340(3):887-893, 2006. e-Pub 2006.
142. Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 174(4 Pt 1):1262-5, 2005. e-Pub 2005. PMID: 16145389.
143. Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL, The ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228-42, 2005. e-Pub 2005. PMID: 16096414.
144. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-702, 2005. e-Pub 2005. PMID: 16030104.
145. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64(1):40-9, 2005. e-Pub 2005. PMID: 15651067.
146. Cho-Vega JH, Troncoso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol 18(4):577-84, 2005. e-Pub 2005. PMID: 15529182.
147. Garg K, Lee P, Ro JY, Qu Z, Troncoso P, Ayala AG. Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol 9(1):11-5, 2005. e-Pub 2005. PMID: 15692945.
148. Ochiai A, Troncoso P, Chen ME, Lloreta J, and Babaian RJ. The Relationship Between Tumor Volume and the Number of Positive Cores in Men Undergoing Multisite Extended Biopsy: Implication for Expectant Management. J of Urol 174(6):2164-2168, 2005. e-Pub 2005.
149. Strom SS, Logothetis CJ, Wang X, Pettaway CA, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following radical prostatectomy. Clin Cancer Res 11(10 Pt. 1):6889-6894, 2005. e-Pub 2005.
150. Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, and McDonald DM. Angiogenesis with Pericyte Abnormalities in a Transgenic Model of Prostate Carcinoma. Cancer 104(10):2104-2115, 2005. e-Pub 2005.
151. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10(20):6770-8, 2004. e-Pub 2004. PMID: 15501953.
152. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 2004. e-Pub 2004. PMID: 15264247.
153. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22(16):3323-9, 2004. e-Pub 2004. PMID: 15310776.
154. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 2004. e-Pub 2004. PMID: 15141384.
155. Naya Y, Ochiai A, Troncoso P, Babaian RJ. A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer. J Urol 171(6 Pt 1):2203-8, 2004. e-Pub 2004. PMID: 15126786.
156. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 2004. e-Pub 2004. PMID: 15102659.
157. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279(18):19191-200, 2004. e-Pub 2004. PMID: 14985354.
158. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol 171(3):1093-7, 2004. e-Pub 2004. PMID: 14767278.
159. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 2004. e-Pub 2004. PMID: 14744752.
160. Vakar-Lopez, Czerniak B, Troncoso P. Atypical Glands Suspicious for Carcinoma Diagnosis in Needle Biopsies of Prostate: A Case Presentation and Review of the Literature with Emphasis on the Clinical Outcome. . Pathology Case Review 8(2):68 – 73, 2004. e-Pub 2004.
161. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27(10):1291-301, 2003. e-Pub 2003. PMID: 14508390.
162. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56(5):1241-7, 2003. e-Pub 2003. PMID: 12873667.
163. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 9(6):2185-94, 2003. e-Pub 2003. PMID: 12796385.
164. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG. Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol 7(2):112-9, 2003. e-Pub 2003. PMID: 12715337.
165. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97(7):1630-8, 2003. e-Pub 2003. PMID: 12655519.
166. Chu LW, Troncoso P, Johnston DA, Liang JC. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 36(3):303-12, 2003. e-Pub 2003. PMID: 12557230.
167. DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T, Prendergast GC. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem 88(3):635-42, 2003. e-Pub 2003. PMID: 12532338.
168. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21(1):57-63, 2003. e-Pub 2003. PMID: 12496764.
169. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 60(5):836-40, 2002. e-Pub 2002. PMID: 12429311.
170. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20(14):3072-80, 2002. e-Pub 2002. PMID: 12118020.
171. Merchant SH, Herman CM, Amin MB, Ro JY, Troncoso P. Myelolipoma associated with adrenal ganglioneuroma. Arch Pathol Lab Med 126(6):736-7, 2002. e-Pub 2002. PMID: 12033969.
172. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 2002. e-Pub 2002. PMID: 12173328.
173. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8(5):1148-54, 2002. e-Pub 2002. PMID: 12006531.
174. Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, Babaian RJ. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 167(4):1675-80, 2002. e-Pub 2002. PMID: 11912386.
175. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8(3):775-81, 2002. e-Pub 2002. PMID: 11895908.
176. Okihara K, Kamoi K, Lane RB, Evans RB, Troncoso P, Babaian RJ. Role of systematic ultrasound-guided staging biopsies in predicting extraprostatic extension and seminal vesicle invasion in men with prostate cancer. J Clin Ultrasound 30(3):123-31, 2002. e-Pub 2002. PMID: 11948567.
177. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121-7, 2002. e-Pub 2002. PMID: 11821895.
178. Ruiz M, Troncoso P, Bruns C, Bar-Eli M. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin Cancer Res 7(12):4086-95, 2001. e-Pub 2001. PMID: 11751506.
179. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48(4):319-26, 2001. e-Pub 2001. PMID: 11710633.
180. Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91(8):1414-22, 2001. e-Pub 2001. PMID: 11301387.
181. Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan J. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q. Oncogene 20(18):2273-80, 2001. e-Pub 2001. PMID: 11402322.
182. Allsbrook WC, Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 32(1):74-80, 2001. e-Pub 2001. PMID: 11172298.
183. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, Troncoso P, Scardino PS, Wheeler TM, Amos CI, Spitz MR. Leptin and prostate cancer. Prostate 46(1):62-7, 2001. e-Pub 2001. PMID: 11170133.
184. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 89(8):1800-9, 2000. e-Pub 2000. PMID: 11042576.
185. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295-2308, 2000. e-Pub 2000. PMID: 10873080.
186. Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, Wheeler T, Amos CI, von Eschenbach A, Kagan J. Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer 89(3):259-64, 2000. e-Pub 2000. PMID: 10861502.
187. Kamoi K, Troncoso P, Babaian RJ. Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia. J Urol 163(3):819-23, 2000. e-Pub 2000. PMID: 10687984.
188. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18(5):1050-7, 2000. e-Pub 2000. PMID: 10694556.
189. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-7, 2000. e-Pub 2000. PMID: 10741751.
190. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163(1):152-7, 2000. e-Pub 2000. PMID: 10604335.
191. Yin Z, Spitz MR, Babaian RJ, Strom SS, Troncoso P, Kagan J. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3. Oncogene 18(52):7576-83, 1999. e-Pub 1999. PMID: 10602517.
192. Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41(3):166-72, 1999. e-Pub 1999. PMID: 10517874.
193. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27(5):362-7, 1999. e-Pub 1999. PMID: 10550525.
194. Chen ME, Troncoso P, Tang K, Babaian RJ, Johnston D. Comparison of prostate biopsy schemes by computer simulation. Urology 53(5):951-60, 1999. e-Pub 1999. PMID: 10223489.
195. Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ. Prostate cancer detection: relationship to prostate size. Urology 53(4):764-8, 1999. e-Pub 1999. PMID: 10197853.
196. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol 161(2):509-14, 1999. e-Pub 1999. PMID: 9915437.
197. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model Systems of Prostate Cancer: Uses and Limitations. Cancer and Metastasis Rev 17:361-371, 1999. e-Pub 1999.
198. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161(1):304-8, 1999. e-Pub 1999. PMID: 10037428.
199. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 106(2):105-9, 1998. e-Pub 1998. PMID: 9797773.
200. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol 160(2):437-42, 1998. e-Pub 1998. PMID: 9679893.
201. Pisters LL, Troncoso P, Navone N. Prolonged survival with metastatic prostate cancer to bone. J Urol 159(6):2100, 1998. e-Pub 1998. PMID: 9598540.
202. Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 159(4):1251-9, 1998. e-Pub 1998. PMID: 9507847.
203. Rajagopal S, Navone NM, Troncoso P, Fritsche HA, Chakrabarty S. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: comparative analyses of MDA PCa2a with established cell lines. Int J Oncol 12(3):589-95, 1998. e-Pub 1998. PMID: 9472097.
204. Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer 79(1):82-90, 1998. e-Pub 1998. PMID: 9495364.
205. Kojima M, Troncoso P, Babaian RJ. Influence of noncancerous prostatic tissue volume on prostate-specific antigen. Urology 51(2):293-9, 1998. e-Pub 1998. PMID: 9495714.
206. Amin MB, Grignon DJ, Bostwick DG, Epstein JI, Reuter VE, Troncoso P, Ro JY, Ayala AG. Recommendations for Reporting Resected Prostatic Carcinomas. . Path Case Rev 3:223-232, 1998. e-Pub 1998.
207. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3(12 Pt 1):2493-500, 1997. e-Pub 1997. PMID: 9815652.
208. Chen ME, Troncoso P, Johnston DA, Tang K, Babaian RJ. Optimization of prostate biopsy strategy using computer based analysis. J Urol 158(6):2168-75, 1997. e-Pub 1997. PMID: 9366337.
209. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV, Steck PA. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5, 1997. e-Pub 1997. PMID: 9393738.
210. Helpap B, Bonkhoff H, Cockett A, Montironi R, Troncoso P, Waters D, Bostwick D. Relationship between atypical adenomatous hyperplasia (AAH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma. Pathologica 89(3):288-300, 1997. e-Pub 1997. PMID: 9270265.
211. Devoll RE, Pinero GJ, Appelbaum ER, Dul E, Troncoso P, Butler WT, Farach-Carson MC. Improved immunohistochemical staining of osteopontin (OPN) in paraffin-embedded archival bone specimens following antigen retrieval: anti-human OPN antibody recognizes multiple molecular forms. Calcif Tissue Int 60(4):380-6, 1997. e-Pub 1997. PMID: 9075637.
212. Pollack A, Troncoso P, Zagars GK, von Eschenbach AC, Mak AC, Wu CS, Terry NH. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation. Prostate 31(1):21-8, 1997. e-Pub 1997. PMID: 9108882.
213. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157(2):569-74, 1997. e-Pub 1997. PMID: 8996359.
214. Wang RY, Troncoso P, Palmer JL, El-Naggar AK, Liang JC. Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression. Clin Cancer Res 2(9):1553-8, 1996. e-Pub 1996. PMID: 9816332.
215. Montironi R, Bostwick DG, Bonkhoff H, Cockett AT, Helpap B, Troncoso P, Waters D. Origins of prostate cancer. Cancer 78(2):362-5, 1996. e-Pub 1996. PMID: 8674018.
216. Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Ayala AG. Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 105(6):667-70, 1996. e-Pub 1996. PMID: 8659439.
217. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11(10):2121-6, 1995. e-Pub 1995. PMID: 7478532.
218. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 154(5):1808-12, 1995. e-Pub 1995. PMID: 7563353.
219. Epstein JI, Grignon DJ, Humphrey PA, McNeal JE, Sesterhenn IA, Troncoso P, Wheeler TM. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19(8):873-86, 1995. e-Pub 1995. PMID: 7611534.
220. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154(1):293-8, 1995. e-Pub 1995. PMID: 7539865.
221. Fornage BD, Dinney CP, Troncoso P. Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. J Clin Ultrasound 23(4):263-5, 1995. e-Pub 1995. PMID: 7797666.
222. Kojima M, Troncoso P, Babaian RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 45(5):807-12, 1995. e-Pub 1995. PMID: 7538243.
223. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45(3):470-5, 1995. e-Pub 1995. PMID: 7879337.
224. Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55(6):1215-20, 1995. e-Pub 1995. PMID: 7533659.
225. El-Naggar AK, Troncoso P, Ordonez NG. Primary renal carcinoid tumor with molecular abnormality characteristic of conventional renal cell neoplasms. Diagn Mol Pathol 4(1):48-53, 1995. e-Pub 1995. PMID: 7735556.
226. Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, Ordonez NG, Ayala AG. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18(12):1224-32, 1994. e-Pub 1994. PMID: 7977945.
227. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 54(24):6370-3, 1994. e-Pub 1994. PMID: 7987830.
228. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44(6):869-75, 1994. e-Pub 1994. PMID: 7527168.
229. Ratoosh SL, Cohen PR, Troncoso P. Cutaneous-malignancy and leprosy: Report of a patient with Mycobacterium leprae and basal cell carcinoma concurrently present in the same lesion. J Dermatol Surg Oncol 20:613-8, 1994. e-Pub 1994. PMID: 8089361.
230. Malpica A, Ro JY, Troncoso P, Ordonez NG, Amin MB, Ayala AG. Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. Hum Pathol 25(4):390-5, 1994. e-Pub 1994. PMID: 7512941.
231. El-Sharkawy, Sahin A, Troncoso P, Sneige N. DNA Ploidy by Image Analysis in the Histologic Classification of Ductal Carcinoma in Situ of Breast (DCIS). . CMB 1:369-375, 1994. e-Pub 1994.
232. Kagan J, Pisters LL, Troncoso P, Young-son J, Parat JM, Babaian RJ, von Eschenbach AC. Genetic Instability in Microsatellite Sequences in Prostate Cancer. International Journal of Oncology 5:921-924, 1994. e-Pub 1994.
233. Zhau HE, Pisters LL, Hall MC, Zhao LS, Troncoso P, Pollack A, Chung LW. Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl 19:208-16, 1994. e-Pub 1994. PMID: 7529853.
234. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 9(1):19-27, 1994. e-Pub 1994. PMID: 7507696.
235. Raslan WF, Ro JY, Ordonez NG, Amin MB, Troncoso P, Sella A, Ayala AG. Primary carcinoid of the kidney. Immunohistochemical and ultrastructural studies of five patients. Cancer 72(9):2660-6, 1993. e-Pub 1993. PMID: 8402487.
236. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85(20):1657-69, 1993. e-Pub 1993. PMID: 7692074.
237. Hammar S, Troncoso P, Yowell R, Mackay B. Use of electron microscopy in the diagnosis of uncommon lung tumors. Ultrastruct Pathol 17(3-4):319-51, 1993. e-Pub 1993. PMID: 8266597.
238. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24):6940-4, 1992. e-Pub 1992. PMID: 1458483.
239. Grignon DJ, Ro JY, Srigley JR, Troncoso P, Raymond AK, Ayala AG. Sclerosing adenosis of the prostate gland. A lesion showing myoepithelial differentiation. Am J Surg Pathol 16(4):383-91, 1992. e-Pub 1992. PMID: 1373581.
240. Miyashita H, Troncoso P, Babaian RJ. BCG-induced granulomatous prostatitis: a comparative ultrasound and pathologic study. Urology 39(4):364-7, 1992. e-Pub 1992. PMID: 1557848.
241. Lloreta-Trull J, Mackay B, Troncoso P, Ribalta-Farres T, Smith T, Khorana S. Neuroendocrine tumors of the nasal cavity: an ultrastructural and morphometric study of 24 cases. Ultrastruct Pathol 16(1-2):165-75, 1992. e-Pub 1992. PMID: 1557819.
242. Babaian RJ, Troncoso P, Ayala A. Transurethral-resection zone prostate cancer detected at cystoprostatectomy. A detailed histologic analysis and clinical implications. Cancer 67(5):1418-22, 1991. e-Pub 1991. PMID: 1991306.
243. Catalano MF, Levin B, Hart RS, Troncoso P, DuBrow RA, Estey EH. Granulocytic sarcoma of the colon. Gastroenterology 100(2):555-9, 1991. e-Pub 1991. PMID: 1985052.
244. Troncoso P, Babaian RJ, Ro JY, Grignon DJ, von Eschenbach AC, Ayala AG. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology 34(6 Suppl):52-6, 1989. e-Pub 1989. PMID: 2603286.
245. Troncoso P, Dytch HE, Bibbo M, Wied GL, Dawson PJ. The significance of DNA measurements in a histologically defined subset of infiltrating ductal carcinomas of the breast with long-term follow-up. Anal Quant Cytol Histol 11(3):166-72, 1989. e-Pub 1989. PMID: 2545218.
246. Grignon DJ, El-Naggar A, Green LK, Ayala AG, Ro JY, Swanson DA, Troncoso P, McLemore D, Giacco GG, Guinee VF. DNA flow cytometry as a predictor of outcome of stage I renal cell carcinoma. Cancer 63(6):1161-5, 1989. e-Pub 1989. PMID: 2917319.
247. Fornage BD, Babaian RJ, Troncoso P. [Diagnosis of early prostatic cancer. Correlation of in vitro echography and histopathologic mapping]. Ann Radiol (Paris) 32(5):415-9, 1989. e-Pub 1989. PMID: 2692503.
248. Sneige N, White VA, Katz RL, Troncoso P, Libshitz HI, Hortobagyi GN. Ductal carcinoma-in-situ of the breast: fine-needle aspiration cytology of 12 cases. Diagn Cytopathol 5(4):371-7, 1989. e-Pub 1989. PMID: 2558863.
249. Ayala AG, Ro JY, Babaian R, Troncoso P, Grignon DJ. The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13(1):21-7, 1989. e-Pub 1989. PMID: 2909195.
250. Ro JY, Grignon DJ, Troncoso P, Ayala AG. Mucin in prostatic adenocarcinoma. Semin Diagn Pathol 5(3):273-83, 1988. e-Pub 1988. PMID: 2459752.
251. Troncoso P, Ordoñez NG, Raymond AK, Mackay B. Malignant Granular Cell Tumor: Immunocytochemical and Ultrastructural Observations. Ultrastruct Pathol 12:137-144, 1988. e-Pub 1988.
252. Ro JY, Grignon DJ, Troncoso P, Ayala AG. Intraluminal crystalloids in whole-organ sections of prostate. Prostate 13(3):233-9, 1988. e-Pub 1988. PMID: 3211805.
253. Troncoso P, Ordonez NG, Mackay B. Soft-tissue tumors. Clin Lab Med 7(1):249-60, 1987. e-Pub 1987. PMID: 3549128.
254. Mehlman DJ, Troncoso P, Hay R, Glagov S. Midsystolic click accompanying isolated bicuspid pulmonic valve. Am Heart J 103:145-7, 1982. e-Pub 1982. PMID: 6459731.
255. Ranasinghe WKB, Andrews JR, Elsheshtawi M, Zhang M, Adibi M, Chery L, Gregg JR, Papadopoulos JN, Pettaway CA, Pisters LL, Ward JF, Davis J, Chapin BF, Troncoso P, Bathala TK. Preoperative mpMRI in surgical planning for the highly aggressive ductal prostate cancer. BJU International.
256. Aparicio A, Tidwell-Slack R, Yadav SS, Chen JS, Zhang M, Troncoso P, Wang W, Guo S, Zhang J, Liu J, Jindal S, Pilie PG, Viscuse PV, Corn PG, Zurita A, Subudhi SK, Allison JP, Sharma P, Logothetis C. Molecular and immune profiles linked to androgen response categories in metastatic castration-resistant prostate cancer (mCRPC). Science Translational Medicine.

Review Articles

1. Fang A, Frigo DE, Hahn A, Razouki Z, Hwang J, Koutroumpakis E, Lawen T, Smith M, Hamilton-Reeves J, DiGiovanni J, Higgason N, Garcia RS, Chapin BF, Pettaway C, Chery L, Troncoso P, Logothetis C, Daniel CR, Wei P, Gregg JR. GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials. Urology 201:152-158, 2025. e-Pub 2025. PMID: 40348027.

Professional Educational Materials

1. . Prostate Tissue Bank Manual, 2006.

Abstracts

1. Pilie PG, Troncoso P, Zhang M. Integrating Tissue-Based Insights to Optimize ARPi+PARPi Therapy in Hormone Sensitive Prostate. 32nd Annual Prostate Cancer Foundation Scientific Retreat, 2025. e-Pub 2025.
2. Zhang M, Zhu K, Kang H C, Logothetis C J, Pilie P G, Troncoso P. Towards the Development of Pathological Criteria of Early Resistance to Androgen Ablation in Sequential Prostate Biopsies. 115th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (2026 USCAP). e-Pub 2025.
3. Frank SJ, Vikram R, Troncoso P, Pettaway CA, Tamboli P, Czerniak BA. Post Radiation Adenocarcinoma of the Urethra: A Clinicopathologic Study of 10 Cases. 115th 2026 Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (2026 USCAP). e-Pub 2025.
4. Subudhi SK, Siddiqui BA, Chapin BF, Basu S, Jindal S, Bataki E, Zhang M, Zhu K, Troncoso P, Sandigursky S, Miller E, Skokos D, Sims JS, Moesta A, Mezzancello M, Seebach F, Lowy I, Tidwell RS, Soule H, Allison J, Sharma P. A pilot presurgical trial of nezastomig (costimulatory PSMAxCD28 bispecific antibody) in patients with high-risk, localized prostate cancer followed by radical prostatectomy. 32nd Annual Prostate Cancer Foundation Scientific Retreat, 2025. e-Pub 2025.
5. Sanchis P, Sabater A, Bizzotto J, Pascual G, Anselmino N, Dong JB, Yang J, Manyam G, Broom B, Shi ZC, Huang SX, Seniuk R, Dondossola E, Panaretakis T, Araujo J, Shepherd P, Troncoso P, Navone N, Logothetis CJ, Frigo DE, Vazquez E, Corn P, Gueron G, Labanca E. Fracturing the tumor-bone alliance in metastatic prostate cancer with Ra223. Cancer Research 85(8), 2025. e-Pub 2025.
6. Zhang M, Vikram R, Sircar K, Troncoso P, Guo C, Tamboli P, Czerniak B. Primary Adenocarcinoma of the Urethra: A Clinicopathologic Study of 48 Cases. 114th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP); Laboratory Investigation 105(3):132-133, 2025. e-Pub 2025.
7. Ranasinghe W, Delavar M, Lawrence MG, Choo N, Niranjan B, Papagiris M, Kraska J, Wang H, Keerthikumar S, Manyam GC, Troncoso P, Shephard PS, Thompson TC, Taylor R, Chapin BF, Risbridger G. Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) combination therapy. Journal of Clinical Oncology 43(Suppl 5/Abstract 420), 2025. e-Pub 2025.
8. Siddiqui B, Chapin B, Basu S, Jindal S, Zhang M, Troncoso P, Zhu K, Sandigursky S, Miller E, Skokos D, Sims J, Mezzancello M, Seebach F, Lowy I, Tidwell R, Soule H, Sharma P, Subudhi S. A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy. 2024 SITC 39th Annual Meeting Abstract; Journal for ImmunoTherapy of Cancer, 2024. e-Pub 2024.
9. Hassanzadeh CJ, Kuban DA, Pasyar S, Bassett R, Troncoso P, Ansari MA, Schlembach PJ, McGuire SE, Nguyen QN, Frank SJ, Mok H, Mohamad O, Park RJH, Shah SJ, Mayo LL, Tang C, Du W, Kudchadker R, Choi S, Hoffman KE. Hypofractionated, Dose-Escalated Radiation vs Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics; Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) 120(2):S56, 2024. e-Pub 2024.
10. Surasi DS, Bathala T, Choi S, Shah S, Nguyen QN, Hoffman K, Mayo L, Mok H, Frank S, Fang A, Sheth R, Hwang KP, Mawlawi O, Macapinlac H, Troncoso P, Zhang M, Pasyar S, Bassett R, Chapin B, Tang C. A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Prostatectomy. American Society for Radiation Oncology (ASTRO) 2024(Abstract 64845):Session #QP 01, 2024. e-Pub 2024.
11. Siddiqui BA, Chapin BF, Basu S, Jindal S, Zhang M, Troncoso P, Zhu K, Martini L, Ravizzini G, Sandigursky S, Miller E, Skokos D, Sims J, Mezzancello M, Seebach F, Lowy I, Tidwell R S, Soule H, Sharma P, Subudhi S K. A pilot presurgical trial of nezastomig (REGN5678, PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy. The 2024 Prostate Cancer Foundation Annual Meeting. Accepted Poster presentation. Accepted, 2024. e-Pub 2024.
12. Weranja R, Melbourne A, Troncoso P, Lawrence M, Choo N, Niranjan B, Papargiris M, Wang H, Ryan A, Shepherd P, Broom B, Manyam G, Taylor R, Thompson T, Navone N, Risbridger G, Chapin B. Using Genomic And Transcriptomic Properties To Determine Androgen Response In Ductal Prostate Cancers And Determine Efficacy Of Poly(Adp-ribose) Polymerase Inhibitors With Androgen Signalling Inhibitors Therapy In Vitro. The Journal of Urology; American Urological Association (AUA) Annual Meeting 209(Abstract PD04-02):Supplement 4, 2023. e-Pub 2023.
13. Mak, CSL, Zhu, M, Liang, X, Wang, F, Hoang, A, Song, X, Shepherd, P, Liang, D, Suh, J, Park, J, Zhang, M, Metzger, E, Schule, R, Jain, A, Karasik, E, Foster, B, Lee, MG, Corn, P, Logothetis, CJ, Aparicio, A, Navone, N, Troncoso P, Zhang, JH, Lin, SH, Wang, G. KDM4A promotes NEPC progression through regulation of MYC expression. 14th Annual Meeting of the American Association for Cancer Research (AACR) 83(7), 2023. e-Pub 2023.
14. Williamson, S, Alaghehbandan, R, Amin, A, Amin, M, Aron, M, Brimo, F, Chan, E, Cheng, L, Colecchina, M, Dhillon J, Downes, M, Evans, A, Harik, L, Hassan, O, Haider, A, Humphrey, P, Jha, S, Kandukuri, S, Kao, CS, Kaushal, S, Khani, F, Kryvenko, O, Kweldam, C, Lal, P, Lobo, A, Maclean, F, Magi-Galluzzi, C, Mehra, R, Menon, S, Miyamoto, H, Mohanty, S, Montironi, R, Nesi, G, Netto, G, Nguyen, J, Nourieh, M, Osunkoya, A, Paner, G, Sangoi, A, Shah, R, Srigley, J, Tretiakova, M, Troncoso P, Trpkov, K, Van Der Kwast, T, Zhang, M, Zynger, D, Giannico, G. Current Practices in Prostate Pathology Reporting: Results From A Survey of Genitourinary Pathologists. Mod Path; 112th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 103(3):S826-S827, 2023. e-Pub 2023.
15. Magill RG, Davis JW, Pettaway C, Pister L, Ward JF, Chapin BF, Papadopolous J, Adibi M, Chery L, Guerrero M, Zhang M, Troncoso P, Gregg JR. Association Of Body Mass Index With Tumor Zonal Origin And Pathologic Features At Radical Prostatectomy. Society of Urologic Oncology Meeting. December 2022. San Diego, CA(Poster Presentation), 2022. e-Pub 2022.
16. Viscuse, PV, Tidwell R, Liu JJ, Guo S, Vundavilli H, Zhang M, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang JB, Pilie PG, Troncoso P, Zhnag JH, Wang WY, Logothetis C, Aparicio A. DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC. J Clin Oncol; Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 40(Abstract 5059):Supplement S; Issue 16, 2022. e-Pub 2022.
17. Zhao Y, Ramesh N, Sei E, Hu M, Bai S, Troncoso P, Logothetis C, Navin N, Zurita A. Investigating longitudinal therapeutic resistance in serially treated metastatic castration resistant prostate cancer by liquid biopsy genome sequencing. American Association of Cancer Research (AACR) Annual Meeting 82(Abstract 3791):Supplement S; Issue 12, 2022. e-Pub 2022.
18. Pieretti AC, Kang HC, Choi H, Zhang M, Chapin BF, Ward JF, Troncoso P, Gregg JR. Role of MRI in defining focal therapy templates in patients with intermediate-risk prostate cancer. American Urological Association (AUA) Annual Meeting 207(Abstract MP55-03):pp.E937-E937 Supplement S Issue 5, 2022. e-Pub 2022.
19. Park PYS, Gao M, Wang X, Hwang H, Surasi DS, Anderson M, Ibarra JR, Javadi S, Morani A, Szklaruk J; Marcal L, Surabhi V, Bhosale P, Adibi M, Chapin BF, Chery LJ, Davis JW, Papadopoulos JN; Pettaway CA; Ward JF, Tang C, Choi S, Zhang M, Pisers L, Troncoso P, Bathala TK. Diagnostic performance of multiparametric MRI in the evaluation of ratio-recurrent prostate cancer using the Prostate Imaging for Recurrence Reporting guidelines (PI-RR) and histopathologic correlation. Society of Abdominal Radiology (SAR) Annual Meeting, 2022. e-Pub 2022.
20. Davis J, Chapin B, Pettaway C, Chery L, Pisters L, Ward, J, Papadopoulos J, Kamat A, Lozano M, Troncoso P, Logothetis C. Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Reduce the Frequency of Pathologic Features that Drive Post-Operative Radiation Therapy. Journal of Urology; Annual Meeting of the American Urological Association (AUA) 206(Abstract PD61-11):E1070-E1071, 2021. e-Pub 2021.
21. Viscuse PV, Zhang M, Liu JJ, Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo, JC, Wang J, Efstathiou E, Wang JB, Pilie PG, Troncoso P, Zhang JH, Logothetis C, Aparicio A. Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial. J Clin Oncol; Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 39(Abstract 83):Issue 6, 2021. e-Pub 2021.
22. Viscuse PV, Zhang M, Liu JJu, Tidwell RS, Subudhi SK, Zurita AJ, Corn P, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang JB, Pilie PG, Troncoso P, Zhang JH, Logothetis C, Aparicio A. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. J Clin Oncol; Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 38(Abstract 156), 2020. e-Pub 2020.
23. Zhang M, Aparicio A, Wang XM, Chapin BF, Troncoso P. Aggressive Variant Prostate Cancer in Men with Hormone Naive, de novo Metastatic Prostate Cancer (M1PC). Mod Pathol; 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 33(Abstract 1041), 2020. e-Pub 2020.
24. Efstathiou E, Boukovala MA, Spetsieris N, Wen SJ, Hoang A, Weldon JA, Tidwell R, Davis JW, Chapin BF, Corn PG, Subudhi SK, Aparicio A, Pettaway CA, Pisters LL, Papadopoulos JN, Adibi M, Wang J, Zurita AJ, Logothetis C, Troncoso P. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC). J Clin Oncol; Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 38(Abstract 5504), 2020. e-Pub 2020.
25. Chery L, Gonzalez GMN, Gu J, Sreekumar A, Jones J, Griffith D, Canfield S, Wang XM, Huang XL, Roberson P, Troncoso P, Ittmann M, Scheurer M, Irizarry-Ramirez M, Pettaway C. SNP RS7824364 Increases The Risk of a Positive Prostate Cancer Biopsy: Results From The Prediction of Prostate Cancer Among African American and Puerto Rican Men (POPCAP) Study. Journal of Urology; Annual Meeting of the American Urological Association (AUA) 203(Abstract MP81-20), 2020. e-Pub 2020.
26. Zhang M, Aparicio A, Chapin BF, Troncoso P. Morphological and Molecular Characterization of Prospectively and Sequentially Analyzed Prostate Tumors from Men with Castration Sensitive, de novo Metastatic Prostate Cancer (M1PCa). Laboratory Investigation; 108th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 32(Abstract 990), 2019. e-Pub 2019.
27. Aparicio A, Zhang M, Ramesh N, Wang XM, Corn PG, Zurita AJ, Amado J, Davis JW, Pettaway CA, Adibi M, Mcguire SE, Tu SM, Wang J, Subudhi SK, Elsheshtawi MA, Efstathiou E, Logothetis C, Navin N, Troncoso P, Chapin BF. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). J Clin Oncol; Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 37(Abstract 5052), 2019. e-Pub 2019.
28. Zurita AJ, Tidwell RS, Troncoso P, Chapin BF, Harris D, Pisters LL, Araujo JC, Pettaway CA, Aparicio, A, Tu SM, Papadopoulos JN, Wang J, Logothetis C, Pagliaro LC, Davis JW. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis. J Clin Oncol; Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 37(Abstract 5078), 2019. e-Pub 2019.
29. Philip N, Pugh TJ, Ye R, Hwang H, Wang X, Shah SJ, Choi S, Mahmood U, Nguyen QN, Chun SG, Mayo LL, Lee AK, Tang C, Anscher MS, Hoffman KE, Kuban DA, Davis JW, Troncoso P, Choi H, Frank SJ. A Phase II trial of Hypofractionated Proton Therapy in Prostate Cancer: 3-year Physician and Patient Reported Outcomes. International Journal of Radiation Oncology Biology Physics; Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) 105(Abstract 2691):E302-E302, 2019. e-Pub 2019.
30. Gao JJ, Ward JF, Pettaway CA, Shi LZ, Subudhi SM, Vence LM, Zhao H, Chen J, Chen H, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, Blando JM, Sepulveda MA, Sun JJ, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 35(Suppl/Abstract 5081), 2017. e-Pub 2017.
31. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Achim MF, Wang X, Choi S, Kuban DA, Troncoso P, Logothetis C, Thompson TC, Kim J. Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 34(15/Abstract 5052), 2017. e-Pub 2017.
32. Achim M, Matin S, Chapin B, Troncoso P, Li E, Tapia N, Guerrero M, Prokhorov I, Olson A, Haddad Z, Margrave J, Chelliserry J, Lam L, Yousefi K, Buerki C, Davicioi E, Davis J. Assessing decipher for predicting lymph node positive disease among men diagnosed with intermediate risk disease treated with prostatectomy and EPLND. J of Urol; Annual Meeting of the American Urological Association (AUA) 197(Suppl S/Abstract MP64-12), 2017. e-Pub 2017.
33. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Gao J, Vence LM, Blando JM, Corn CG, Araujo JC, Zurita AJ, Prokhorova IN, Alstine MV, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 35(Suppl/Abstract 5065), 2017. e-Pub 2017.
34. Troncoso P, Li-Ning Tapia E, Davis JW, Wang X, Prokhorova I, Pisters L, Pettaway C, Efstathiou E. Cribriform/Intraductal Carcinoma, a Candidate Predictor of Response to Neoadjuvant Treatment with Novel Androgen Inhibitors in Localized High Risk Prostate Cancer. Mod Pathol; USCAP 2017 Annual Meeting(Abstract 1064), 2017. e-Pub 2017.
35. Aparicio A, Xiao L, Li Ning Tapia E, Hoang A, Ramesh N, Wu W, Chancoco, Heath EI, Efstathiou E, Thompson TC, Troncoso P, Broom BM, Zurita AJ, Navin N, Logothestis C, Corn PG. The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 35(Suppl/Abstract 5013), 2017. e-Pub 2017.
36. Zurita AJ, Carlsson A, Troncoso P, Hicks J, Logothetis CJ, Kuhn P. High-definition single cell analysis (HD-SCA) reveals enrichment in androgen receptor (AR) expression in tumor cell clusters in bone marrow and blood of metastatic castration-resistant prostate cancer (mCRPC) patients. AACR 2016 Annual Meeting Section 25(Abstract 4966), 2016. e-Pub 2016.
37. Corn PG, Tapia EL, Xiao L, Heath EI, Chancoco H, Hoang A, Efstathiou E, Thompson TC, Troncoso P, Logothetis C, Aparicio A. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 34(Suppl/Abstract 5020), 2016. e-Pub 2016.
38. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Achim MF, Wang X, Choi S, Kuban DA, Troncoso P, Logothetis C, Thompson TC, Kim J. Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 34(Suppl/Abstract 5052), 2016. e-Pub 2016.
39. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 34(Suppl/Abstract e14506), 2016. e-Pub 2016.
40. Zurita AJ, Carlsson A, Troncoso P, Hicks J, Logothetis CJ, Kuhn P. High-definition single cell analysis (HD-SCA) reveals enrichment in androgen receptor (AR) expression in tumor cell clusters in bone marrow and blood of metastatic castration-resistant prostate cancer (mCRPC) patients. AACR 107th Annual Meeting on Bioinformatics and Systems Biology 76(Supp 14; Abstract 4966), 2016. e-Pub 2016.
41. Efstathiou E, Tsikkinis A, Wen S, Tapia ELN, Hoang A, Aparicio A, Tu SM, Rangel G, Troncoso P, Corn P, Araujo J, Logothetis C. Abiraterone acetate (AA) followed by randominization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC). 41st Congress of the European Society for Medical Oncology (ESMO) 27(Suppl 6/Abstract 727PD), 2016. e-Pub 2016.
42. Troncoso P, Davis JW, Tapia EL, Prokhorova I, Ward JF, Pisters LL, Achim M, Logothetis CJ, Kim J. Prostate Cancer Gleason Grade 4 Pattern Heterogeneity in Men on Active Surveillance Who Undergo Delayed Prostatectomy. Mod Pathol; USCAP 2016 Annual Meeting(Abstract 1061), 2016. e-Pub 2016.
43. Zurita AJ, Carlsson A, Luttgen MS, Bethel K, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis C, Kuhn P. A clinically applicable strategy to concurrently profile prostate cancer (PCa) in circulation and bone using high-definition single cell analysis (HD-SCA). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 34(Suppl/Abstract 5041), 2016. e-Pub 2016.
44. Efstathiou E, Davis JW, Titus MA, Chapin BF, Zurita AJ, Wen S, Tapia EL, Hoang A, Corn PG, Wang X, Whittington F, Troncoso P, Logothetis C. Neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer (LHRPC). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 34(Suppl/Abstract 5002), 2016. e-Pub 2016.
45. Aparicio A, Shen L, Li Ning Tapia E, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn PG, Thompson TC, Broom BM, Baggerly KA, Logothetis C, Maity SN. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 33(Suppl/Abstract 5055), 2015. e-Pub 2015.
46. Efstathiou E, Troncoso P, Li Ning Tapia E, Davis JE, Titus MA, Hoang A, Prokhorova IP, Wen S, Logothetis C. Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 33(Suppl/Abstract 5061), 2015. e-Pub 2015.
47. Irizarry-Ramirez M, Kittles R, Wang X, Nogueras-Gonzalez GM, Salgado-Montilla J, Roberson P, Troncoso P, Rivera-Ramon K, Sanchez-Ortiz R, Guerrios L, Soto-Salgado M, Suarez E, Pettaway CA. Ancestry and prostate cancer genetic risk loci in Hispanic Puerto Rican men: Comparative study with African American men. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 33(Suppl/Abstract e16033), 2015. e-Pub 2015.
48. Efstathiou E, Li W, Gormley M, McMullin R, Sokol Ricci D, Davis JW, Li Ning Tapia E, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Logothetis C. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 33(Suppl/Abstract 5005), 2015. e-Pub 2015.
49. Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu SM, Wang J, Le O, Logothetis C, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 33(Suppl/Abstract TPS5075), 2015. e-Pub 2015.
50. Nguyen JN, Chaoin BF, Prokhorova IN, Achim M, Wang X, Davis JW, Troncoso P. Positive margin length and Gleason Garde of tumor Focus at the margin predict for Biochemical failure after radical prostatectomy in patients with PT2 Prostate Cancer. J of Urol; Annual Meeting of the American Urological Association (AUA) 191(Suppl 4s/Abstract MP62-13):e722, 2014. e-Pub 2014.
51. Troncoso P, Nguyen JN, Prokhorova IN, Wang X, Li Ning Tapia EM, Achim MF, Davis JW, Chapin BF. Pathologic Features in Radical Prostatectomy Specimens Associated with Biochemical Failure in Patients with pT2 Prostate Cancer and Positive Surgical Margin. Mod Pathol; USCAP 2014 Annual Meeting 27(Suppl S2/Abstract 1090):264A, 2014. e-Pub 2014.
52. Lis RT, Ye H, True LD, Loda M, Peng W, Kheoh T, Tran NP, Molina A, Kantoff PW, Taplin ME, Troncoso P. A Novel Metric to Assess Tumor Load (TL) in the Neoadjuvant Setting: Data from a Randomized, Phase 2 Trial in Patients (pts) with Localized, High-Risk Prostate Cancer (LHRPC). Mod Pathol; USCAP 2014 Annual Meeting 27(Suppl S2/Abstract 1009):245A, 2014. e-Pub 2014.
53. Davis JW, Achim MF, Ward JF, Pettaway CA, Chapin BF, Wand X, Kuban DA, Frank SJ, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Papadopoulos JN, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Kim J. Active Surveillance in phenotypically heterogeneous early-stage prostate cancer. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 32(Suppl 5s/Abstract 5083), 2014. e-Pub 2014.
54. Zurita AJ, Pagliaro LC, Troncoso P, Davis JW. Presurgical axitinib and androgen deprivation therapy (ADT) in prostate cancer (PCa) patients (pts) presenting with lymph node (LN) metastasis. J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 32(Suppl 5s/Abstract TPS5109), 2014. e-Pub 2014.
55. Efstathiou E, Titus MA, Wen S, SanMiguel A, Hoang A, Hass-Amatsaleh AD, Perabo F, Phung D, Troncoso P, Ouataas T, Logothetis C. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol; Annual Meeting of the American Society of Clinical Oncology (ASCO) 32(Suppl 5s/Abstract 5000), 2014. e-Pub 2014.
56. Richie JP, Montgomery RB, Logothetis CJ, Bubley GJ, Dalkin BL, Sanda MG, Loda MF, Lis RT, True LD, Troncoso P, Genega EM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Haqq CM, Tran N, Peng W, Tamae D, Kheoh T, Molina A, Kantoff PW, Taplin ME. Effect of Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate on PSA, Pathologic Response, Intraprostatic/Serum Androgen Levels in Localized High-Risk Prostate Cancer: Results of a Randomized Phase 2 Study. J of Urol 189(Suppl 4s/Abstract 665):e272, 2013. e-Pub 2013.
57. Kim J, Ward JF, Pettaway CA, Wang X, Kuban DA, Frank SJ, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim AF, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Davis W. Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). J Clin Oncol 31(Suppl 15/Abstract 5069):May 20, 2013. e-Pub 2013.
58. Li Ning Tapia E, Kim J, Efstathiou E, Wang X, Prokhorova, Gorlov I, Amos C, Troncoso P. Linking Markers of Steroid Metabolism, Cell Cycle and Microenvironment to Gleason Score: Towards the Development of a Prognostic Panel. Mod Pathol 26(Suppl 2s/Abstract 954):230A, 2013. e-Pub 2013.
59. Davis JW, Achim M, Matin S, Babaian K, Troncoso P. Management of the Lymph Nodes after Robot-Assisted Radical Prostatectomy: A 4-Strategy Evaluation. Annual Meeting of the South Central Section of the AUA, Colorado Springs, CO, 2012. e-Pub 2012.
60. Davis J, Troncoso P, Meyer S, Day J, Groskopf J, Aubin S, Rodriguez Y, Lin D, Magi-Galluzzi C, Berglund R. Correlation of urine PCA3 score and TMPRSS2:ERG score with clinically significant tumor volume in radical prostatectomy specimens: Interim results form a multi-center prospective study. J of Urol 187(4 Supplement):e852-853, 2012. e-Pub 2012.
61. Sircar K, Huang H, Hu L, Li Y, Dhillon J, Cogdell D, Aprikian A, Navone N, Troncoso P, Zhang W. Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin as a Therapeutic Target in Castration-Resistant Prostate Cancer. Mod Pathol 25(Suppl 2/Abstract 1012):241A, 2012. e-Pub 2012.
62. Tzelepi V, Karlou M, Wen S, Hoang A, Scopa C, Logothetis CJ, Efstathiou E, Troncoso P. Differential Expression of Integrins in Intraductal Spread, Cribriform, and Non-Cribriform Patterns of High Grade Untreated and Treated Prostate Cancer. Mod Pathol 25(Suppl 2/Abstract 1036):246A, 2012. e-Pub 2012.
63. Troncoso P, Matin S, Babaian KN, Prokhorova IN, Davis JW. Correlation between Laterality of Pelvic Lymph Node Metastases and Tumor Laterality in Biopsy and Prostatectomy Specimens from Patients Undergoing Extended Pelvic Lymph Node Dissection (ePLND). Mod Pathol 25(Suppl 2s/Abstract 1032):245-246A, 2012. e-Pub 2012.
64. Taplin, ME, Montgomery RB, Logothetis C, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Loda MF, True LD, Troncoso P, Genega EM, Balk SP, Nelson P, Xie W, Haqq CM, Tran N, Liu CS, Kheoh TS, Molina A, Kantoff P. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. J Clin Oncol 30(Suppl/Abstract 4521), 2012. e-Pub 2012.
65. Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Molina A, Logothetis C. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. J Clin Oncol 30(Suppl 18/Abstract 4556), 2012. e-Pub 2012.
66. Mikulasovich M, Stanton M, Guo CC, Deavers MT, Prokhorova I, Czerniak B, Troncoso P. TMP RSS2-ERG Gene Fusion in Prostate Cancer of Central Zone Origin. Mod Pathol 25(Suppl 2/Abstract 950):227-228A, 2012. e-Pub 2012.
67. Guo CC, Mikulasovich M, Deavers MT, Troncoso P, Czerniak B. ERG Protein Expression and ERG Gene Rearrangement in Prostate Cancers of Different Zonal Origins. Mod Pathol 25(Suppl 2/Abstract 876):210A, 2012. e-Pub 2012.
68. Tzelepi V Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment. J Clin Oncol 29(18):2574-2581, 2011. e-Pub 2011.
69. Efstathiou E, Titus MA, Tsavachidou D, Hoang A, Karlou M, Wen S, Troncoso P, Ashe R, Berman CJ, Mohler J, Logothetis C. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. J Clin Oncol 29(Suppl/Abstract 4501), 2011. e-Pub 2011.
70. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Lin AM, Small EJ, Mathew P, Jones DM, Troncoso P, Thall PH, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29(Suppl/Abstract 4666), 2011. e-Pub 2011.
71. Sircar K, Huang H, Cogdell D, Dhillon J, Tzelepi V, Navone N, Bismar T, Koumakpayi H, Saad F, Aprikian A, Troncoso P, Zhang W. Asparagine Synthetase is a Target in Castration Resistant Prostate Cancer. Mod Pathol 24(Suppl 1/Abstract 948):224A, 2011. e-Pub 2011.
72. Tzelepi V, Maity S, Zhang J, Karlou M, Liang S, Hoang A, Lu J, Kleb B, Efstathiou E, Navone N, Aparicio A, Troncoso P. Differential Expression of UBE2C and ASCL1 in Neuroendocrine Carcinoma and Adenocarcinoma of the Prostate in Xenograft Models and Human Samples. Mod Pathol 24(Suppl 1/Abstract 964):228A, 2011. e-Pub 2011.
73. Kim J, Davis J, Ward J, Wang X, Pettaway C, Pistrs L, Matin S, Kuban D, Frank S, Lee A, Prokhorova I, Brown V, Logothetis C, Troncoso P. Incidence of Reclassification in Patients Undergoing Active Surveillance for Favorable-Risk Prostate Cancer. Mod Pathol 24(Suppl 1\Abstract 859):204A, 2011. e-Pub 2011.
74. Davis JW, Matin S, Babaian RJ, Pettaway C, Pisters L, Prokhorova I, Gonzales G, Munsell M, Troncoso P. Comparative effectiveness of radical prostatectomy modalities: a focus on pathologic endpoints. South Central Section of the American Urological Association,Podium Abstract, 2010. e-Pub 2010.
75. Tzelepi V, Efstathiou E, Troncoso P, Pettaway CA, Hoang A, Logothetis C, Pagliaro LC. Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel. J Clin Oncol 28(Suppl 15s/Abstract 4663), 2010. e-Pub 2010.
76. Efstathiou E, Tu S, Aparicio A, Hoang A, Wen S, Troncoso P, Smith LA, Chieffo N, Molina A, Logothetis C. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(Suppl 15s/Abstract 4547), 2010. e-Pub 2010.
77. Tzelepi V, Karlou M, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Hedgehog Pathway Activation Is Associated with VEGF Induction in Prostate Cancer Microenvironment. Mod Pathol 23(Suppl 1s/Abstract 999):224A, 2010. e-Pub 2010.
78. Guo CC, Wang Y, Xiao L, Prokhorova I, Troncoso P, Czerniak BA. The Relationship of TMPRSS2-ERG Gene Fusion between Primary and Metastatic Prostate Cancers. Mod Pathol 23(Suppl 1s/Abstract 857):193-194A, 2010. e-Pub 2010.
79. Tzelepi V, Maity S, Yang J, Efstathiou E, Aparicio A, Logothetis C, Troncoso P, Navone N. Comparison of Immunohistochemical Profile of Prostate Cancer Tumorgrafts and Their Donor Tumor. Mod Pathol 23(Suppl 1s/Abstract 1000):224A, 2010. e-Pub 2010.
80. Stanton M, Guo CC, Li X, Wang Y, Andino L, Prokhorova IN, Pisters LL, Troncoso P. TMPRSS2-ERG Gene Fusion Status in Salvage Radical Prostatectomy Specimens Following Radiotherapy. Mod Pathol 23(Suppl 1s/Abstract 986):221A, 2010. e-Pub 2010.
81. Sircar K, Cogdell D, Dhillon J, Huang H, Hu L, Navone N, Katz R, Khanna A, Bismar TA, Koumakpayi IH, Saad F, Aprikian AG, Monzon FA, Troncoso P, Zhang W. Integrative Molecular Profiling of Castraction Resistant Prostate Cancer. Mod Pathol 23(Suppl 1s/Abstract 981):220A, 2010. e-Pub 2010.
82. Troncoso P, Matin S, Babaian RJ, Pettaway CA, Pisters LL, Prokhorova I, Davis JW. Positive Margins in pT2 Prostate Cancer in Open, Laparoscopic and Robot-Assisted Radical Prostatectomy Specimens. Mod Pathol 23(Suppl 1s/Abstract 994):222A-223A, 2010. e-Pub 2010.
83. Xiao L, Gong Y, Wang Y, Troncoso P, Czerniak BA, Guo CC. The TMPRSS-2 ERG Gene Fusion in Small Cell Carcinoma of the Prostate. Mod Pathol 23(Suppl 1s/Abstract 1022):229A, 2010. e-Pub 2010.
84. Sharma P, Tsavachidou D, Kamat A, Ng Tand D, Chen H, Fu T, Troncoso P, Wolchok J, Logothetis CJ, Allison JP. Immunologic impact of anti-CTLA-4 therapy. J Clin Oncol 27(Suppl 15s/Abstract 3019), 2009. e-Pub 2009.
85. Sharma P, Kamat A, Tang DN, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Quezada S, Logothetis CJ, Allison JP. Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial. 2009 AACR Annual Meeting(Abstract 5665), 2009. e-Pub 2009.
86. Chiong E, Andino L, Guo CC, Prokhorova IN, Goh JJ, Pisters LL, Troncoso P. Pathologic Features of Salvage Radical Prostatectomy Specimens Following Radiotherapy: Implications for Focal Therapeutic Options. J of Urol 181(4 Suppl 1/Abstract 1284):458, 2009. e-Pub 2009.
87. Ward JF, Graefen M, Huland H, Kollermann J, Sauter G, Wang X, Haese A, Troncoso P, Babaian RJ, Chun FK. PCA3 Score Based Nonogram to Predict Low-Volume/Low-Grade Prostate Cancer in Radical Prostatectomy Specimens. J of Urol 181(4 Suppl 1/Abstract 155):56, 2009. e-Pub 2009.
88. Davis JW, Troncoso P, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim J. Active Surveillance for Localized Prostate Cancer-A Prospective Protocol. J of Urol 181(4 Suppl 1/Abstract 494):177, 2009. e-Pub 2009.
89. Chun FK, Ward JF, Huland H, Kollermannn J, Sauter G, Graefen M, Troncoso P, Babaian RJ, Haese A. Prostate Cancer Antigen 3 (PCA3) Shows Significant Association to Prostate Cancer Volume but no Correlation to Total Prostate Volume or Serum Prostate Specific Antigen. J of Urol 181(4 Suppl 4/Abstract 2127):771-772, 2009. e-Pub 2009.
90. Liang M, Troncoso P, Czerniak BA, Guo CC. Rhabdomyosarcoma of the Urinary Bladder and Prostate in Adults: A Clinicopathologic Study of 11 Cases. Mod Pathol 22(Suppl 1s/Abstract 806):178A, 2009. e-Pub 2009.
91. Andino L, Guo C, Chiong E, Prokhorova IN, Pisters LL, Troncoso P. Pathologic Features of Salvage Radical Prostatectomy Specimens Following Radiotherapy: Implications for Focal Therapeutic Options. Mod Pathol 22(Suppl 1s/Abstract 707):157A, 2009. e-Pub 2009.
92. Dancer JY, Zuo G, Soto C, Troncoso P, Czerniak BA, Guo CC. TMPRSS2-ERG Gene Fusion in Small Cell Carcinoma of the Prostate. Mod Pathol 22(Suppl 1s/Abstract 741):164-165A, 2009. e-Pub 2009. PMID: 21040948.
93. Guo CC, Zuo G, Cao D, Soto C, Troncoso P, Czerniak BA. Prostate Cancer of Transitional Zone Lacks TMPRSS-2 Gene Fusion. Mod Pathol 22(Suppl 1s/Abstract 771):171A, 2009. e-Pub 2009.
94. Davis JW, Kim J, Troncoso P. Radical Prostatectomy findings in patients considered potential candidates for active surveillance. Societe Internationale d'Urologie Oncology, 2008. e-Pub 2008.
95. Davis JW, Troncoso P, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim JW. Active surveillance for clinically localized prostate cancer at a high volume tertiary referral center. Societe Internationale d'Urologie Oncology, 2008. e-Pub 2008.
96. Logothetis CJ, Wen S, Molina A, Chieffo N, Smith LA, Troncoso P, Efstathiou E. Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (Pts) treated with Abiraterone Acetate (AA). J Clin Oncol 26(Suppl /Abstract 5017), 2008. e-Pub 2008.
97. Efstathiou E, Tsavachidou D, Wen S, Troncoso P, Mills GB, Logothetis CJ. Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with temsirolimus with or without androgen ablation. J Clin Oncol 26(Suppl/Abstarct 5071), 2008. e-Pub 2008.
98. Zuria AJ, Ward JF, Araujo JC, Pettaway CA, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26(Suppl/Abstract 16004^), 2008. e-Pub 2008.
99. Zhi-Gang L, Navone N, Yang J, Liu J, Mathew P, Starbuck M, Zurita A, Sikes C, Multani A, Efstathiou E, Lopez A, Wang J, Fanning T, Prieto V, Kundra V, Troncoso P, Raymond A, Lin SW, Vazquez E. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. 2008 AACR Annual Meeting(Abstract 1612), 2008. e-Pub 2008.
100. Pettaway CA, Song R, Wang X, Liu J, McDonnell TJ, Black PC, Prokhorova I, Soto C, Strom S, Troncoso P. Racial variation in the matrix metalloproteinase: E-cadherin ratio in localized prostate cancer: results from a contemporary matched comparative study. J of Urol 179(4 Suppl 4/Abstract 1227):421-422, 2008. e-Pub 2008.
101. Ward JF, Nakanishi H, Babaian RJ, Troncoso P. In-field/out-field prostate cancer foci: multifocality and considerations for the application of focal prostate therapy. J of Urol 179(4 Suppl 1/Abstract 1443):493, 2008. e-Pub 2008.
102. Efstathiou E, Wen S, Molina A, Chieffo N, Smith L, Hoang A, Troncoso P, Logothetis CJ. Candidate predictors of response to abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). 2009 Genitourinary Cancer Symposium(Abstract 187), 2008. e-Pub 2008.
103. Guo CC, Pisters LL, Troncoso P. Involvement of the rectum by prostatic adenocarcinoma in total pelvic exenteration specimens. Mod Pathol 21(Suppl 1s/Abstract 723):159A, 2008. e-Pub 2008.
104. Troncoso P, Davis JW, Ward JF, Wang X, Babaian RJ, Kim J. Radical prostatectomy findings in patients considered potential candidates for active surveillance. Mod Pathol 21(Suppl 1s/Abstract 845):185A, 2008. e-Pub 2008.
105. Sharma P, Liakou C, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C. Effect of CTLA-4 blockade on IFNy-producing CD4+ICOS hi cells and on the ratio of effector to regulatory T cells in cancer patients. 2008 ASCO Molecular Markers(Abstract 16), 2008. e-Pub 2008.
106. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: Torward a classification of prostate cancer in the properative model. 2008 ASCO Genitourinary Cancer Symposium(Abstract 93), 2008. e-Pub 2008.
107. Pettaway CA, Song R, Lin E, Wang X, Soto C, Troncoso P. Prostate biopsy matrix metalloproteinase: E-cadherin expression ratio: Prognostic significance in a contemporary cohort. 2008 ASCO Genitourinary Cancers Symposium(Abstract 26), 2008. e-Pub 2008.
108. Kassouf W, Ochiai A, Babaian KN, Nakanishi H, Troncoso P, Babaian RJ. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. J of Urol 178(1/Abstract 386):111-114, 2007. e-Pub 2007.
109. Mathew P, Li ZG, Liu J, Yang J, Starbuck MW, Sikes C, Multani AS, Wang J, Fanning TV, Prieto VG, Troncoso P, Raymond AK, Lin SH, Navone N. Induction of osteogenesis in osseous and non-osseous sites by an androgen receptor-negative human prostate cancer xenograft. 2007 SPORE Investigators Workshop(Abstract 60), 2007. e-Pub 2007.
110. Liakou C, Ng TD, Hwu P, Pettaway C, Kamat A, Troncoso P, Logothetis C, Liu Y, Sharma P. Ex vivo analysis of prostate cancer tumor-infiltrating lymphocytes demonstrates immunosuppressive CD4+CD25+FOXP3+ and CD4+ICOS+IL-10 producing regulatory T cells. 2007 SPORE Investigators Workshop(Abstract 156), 2007. e-Pub 2007.
111. Kim J, Tsavachidou D, Do K, Wen S, Babaian RJ, Pisters L, Pettaway C, Troncoso P, Logothetis C, McDonnell T. Differential gene expression in preoperative study of selenium and vitamin E chemoprevention in prostate cancer. J Clin Oncol 25(Suppl 18s/Abstract 1523), 2007. e-Pub 2007.
112. Mathew P, Pettaway C, Pisters L, Williams D, Troncoso P, Logothetis C. Preoperative platelet-derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation in high-risk localized prostate cancer. J Clin Oncol 25(Suppl 18s/Abstract 5141), 2007. e-Pub 2007.
113. Efsthathiou E, Troncoso P, Wen S, Do K, Pettaway CA, Logothetis CJ. Coordinated modulation of sonic hedgehog (Shh) signaling and adrogen receptor (AR) in the prostate tumor microenvironment by chemo-hormonal therapy. J Clin Oncol 25(Suppl 18s/Abstract 5066), 2007. e-Pub 2007.
114. Ochiai A, Sotelo T, Troncoso P, Bhadkamkar V, Babaian RJ. Natural history of biochemical progression following radical prostatectomy based on length of a positive margin. 2007 AUA Annual Meeting(Abstract 742), 2007. e-Pub 2007.
115. Nakanishi H, Groskopf J, Bhadkamkar V, Blase A, Kumar S, Davis JW, Troncoso P, Rittenhouse H, Babaian R. The relationship between PCA3 score and tumor volume in prostatectomy samples. 2007 Prostate Cancer Symposium(Abstract 354), 2007. e-Pub 2007.
116. Efstathiou E, Logothetis CJ, Wen S, Do K, Troncoso P. Morphologic heterogeneity within high-grade adenocarcinoma of the prostate: implications for molecular diversity. 2007 Prostate Cancer Symposium(Abstract 66), 2007. e-Pub 2007.
117. Efstathiou E, Wen S, Logothetis CJ, Do KA, McDonnell TJ, Troncoso P. Morphologic heterogeneity of high-grade prostatic adenocarcinoma corresponds to molecular diversity. Mod Pathol 20(Suppl 2s/Abstract 653):145A, 2007. e-Pub 2007.
118. Fine SW, Trock B, Reuter VE, Ayala G, Cheville JC, Fearn P, Jenkins RB, Knudsen BS, Loda M, Netto GJ, Said J, Shah RB, Simko J, Troncoso P, True LD, Yang XJ, Rubin MA, DeMarzo AM. Effects of tissue processing on biomarker analysis in prostate needle biopsies: a multi-institutional study. Mod Pathol 20(Suppl 2s/Abstract 658):146A, 2007. e-Pub 2007.
119. Pettaway CA, Song R, Wang X, Liu J, McDonnell T, Black P, Prokhorova I, Soto C, Strom S, Troncoso P. Racial variation in the matrix metalloproteinase: E-cadherin ratio in localized prostate cancer. 2007 Prostate Cancer Symposium(Abstract 54), 2007. e-Pub 2007.
120. Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Moris MJ, Troncoso P, Bucana CD, Fidler IJ, Logothetis C. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). J Clin Oncol 24(Suppl 18s/Abstract 4562), 2006. e-Pub 2006.
121. Kim J, Wang X, Babaian R, Pisters L, Pettaway C, Wood C, Sabichi A, McDonnell T, Logothetis C, Troncoso P. A preoperative model evaluating the tissue effects of chemopreventive agents in low-volume prostate cancer. J Clin Oncol 24(Suppl 18s/Abstract 1007), 2006. e-Pub 2006.
122. Mathew P, Thall PF, Johnson MM, Wen S, Oh WK, Meluch AA, Morris MJ, Jones D, Troncoso P, Bucana CD, Fidler IJ, Logothetis CJ. Combination of a platelet-derived growth factor receptor inhibitor and chemotherapy in men with metastatic castration-resistant prostate cancer and bone metastases; results of a randomized placebo-controlled trial. 14th SPORE Investigators Workshop:Abstract 183, 2006. e-Pub 2006.
123. Mathew P, Thall P, Johnson M, Oh W, Meluch A, Morris M, Troncoso P, Bucana C, Fidler IJ, Logothetis C. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Inter-Prostate SPORE Meeting, 2006. e-Pub 2006.
124. Cardo-Vila M, Zurita AJ, Giordano RJ, Kolonin MG, Sun J, Lahdenranta J, Rangel R, Ozawa MG, Troncoso P, Gershenwald JE, Logothetis CJ, Almeida F, Arap W, Pasqualini R. Targeting a functional IL-11 receptor site within prostate cancer by combinational screenings in vivo. Inter-Prostate SPORE Meeting, 2006. e-Pub 2006.
125. Efstathiou E, Troncoso P, McDonnell TJ, Logothetis CJ. Thalidomide as a modulator of the stromal epithelial interaction of high-grade prostate cancer. Inter-Prostate SPORE Meeting, 2006. e-Pub 2006.
126. Cho-Vega JH, Tsavachidis S, Do KA, Troncoso P, Medeiros LJ, Lopez R, McDonnell TJ. Dicarbonyl/L-Xylulose Reductase (DCXR): A new potential marker for prostate adenocarcinoma identified by LCM-microSAGE. Lab Invest 86(1):133A, 2006. e-Pub 2006.
127. Vakar-Lopez F, Kim J, Thall PF, Wang X, Zurita A, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Prokhorova IN, McDonnell TJ, Logothetis CJ, Troncoso P. A preoperative model evaluating the tissue effects of chemopreventive agents in clinically localized prostate cancer. Lab Invest 86(1):167A, 2006. e-Pub 2006.
128. Kim J, Troncoso P, Coombes K, Logothetis CJ, McDonnell TJ. Therapy stratification based on dynamic modulation of genetic networks in patients with low-volume prostate cancer. Inter-Prostate SPORE Meeting, 2006. e-Pub 2006.
129. Ochiai A, Vakar-Lopez F, Troncoso P, Babaian RJ. The relationship between PSA and tumor volume persists in current era. 2006 AUA Annual Meeting:Abstract 867, 2006. e-Pub 2006.
130. Pettaway CA, Pisters LL, Troncoso P, Wang X, Brown MA, Busby JE, Spies PE, Millikan RE, Logothetis CJ. Clinical aspects of the high risk neoadjuvant treatment model: five year results. 2006 AUA Annual Meeting:Abstract 962, 2006. e-Pub 2006.
131. Spiess PE, Busby JE, Jordan J, Hernandez M, Troncoso P, Burt K, Lee AK, Taylor SH, Merriman KW, Bassett R, Pisters LL. Radical prostatectomy for lymph node positive prostate cancer: The M. D. Anderson Cancer Center experience. 2006 AUA Annual Meeting:Abstract 966, 2006. e-Pub 2006.
132. Sotelo T, Ochiai A, Troncoso P, Bhadkamkar V, Babaian RJ. Relationship of BMI to pathologic features in radical prostatectomy specimens in men with positive surgical margins. 2005 AUA Annual Meeting, 2005. e-Pub 2005.
133. McDonnell TJ, Do K, Wen S, Troncoso P, Babaian RJ, Pisters L, Pettaway CA, Wood C, Lippman S, Logothetis C, Sabichi A, Xiao L, Zhang L, Kim J. Global gene expression assessment reveal treatment specific and cell type specific responses to selenium and vitamin E in patients with organ-confined prostate cancer. Inter-Prostate SPORE Meeting, 2005. e-Pub 2005.
134. Pettaway CA, Song R, Wang X, Do K, Strom S, Troncoso P. The ratio of matrix metalloproteinase to e-cadherin expression level: prognostic significance of mRNA and protein expression among african american prostate cancer patients. 96th Annual AACR Meeting, 2005. e-Pub 2005.
135. De Marzo AM, Platz EA, Epstein JI, Billis A, Chan TY, Cheng L, Datta M, Ertoy-Baydar D, Farre X, Fine S, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Rubin MA, Sebo T, Sesterhenn IA, Shah R, Signoretti S, Simko J, Troncoso P, Tsuzuki T, GJLH VL, Yang X, Zhou M, Figg WD, Hoque A, Lucia MS. Interobserver Reproducibility of a proposed classification of focal prostate atrophy lesions. Mod Pathol 18(1):135a, 2005. e-Pub 2005.
136. Jacobsohn KM, Kamat AM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of selection criteria used in predicting extraprostatic cancer extension in patients undergoing nerve-sparing radical prostatectomy. 2005 AUA Annual Meeting, 2005. e-Pub 2005.
137. Gomez JA, Tibbs RF, Abrahams NA, Vakar-Lopez F, Troncoso P. Morphologic changes in pelvic lymph node metastases of prostatic adenocarcinoma following neoadjuvant therapy. Mod Pathol 18(1):142a, 2005. e-Pub 2005.
138. Mathew P, Sikes C, Multani A, Bucana C, Prieto V, Troncoso P, Raymond A, Logothetis C, Navone N. Bone morphogenetic proteins (BMPs) and platelet-derived growth factor (PDGF) are expressed in a human prostate cancer xenograft, which induces mouse-derived osteogenesis. 2005 ASCO Prostate Cancer Symposium(Abstract 198), 2005. e-Pub 2005.
139. Pettaway CA, Pisters LL, Troncoso P, Millikan R, Do K, McDonnell T, Logothetis C. Clinical aspects of the high-risk neoadjuvant treatment model: five-year results. 13th SPORE Investigators Workshop(Abstract 162), 2005. e-Pub 2005.
140. Tibbs RF, Abrahams NA, Wang X, Gomez JA, Vakar-Lopez F, Pettaway CA, Pisters LL, Mathew P, McDonnell TJ, Do K, Logothetis CJ, Troncoso P. A morphologic characterization of the spectrum of treated prostate cancer. 13th SPORE Investigators Workshop(Abstract 172), 2005. e-Pub 2005.
141. Kim J, Vakar-Lopez F, Wang X, Thall P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, Lieberman, McDonnell TJ, Sabichi AL, Logothetis CJ, Troncoso P. A preoperative model of clinically localized prostate cancer: The devil is in the details. 13th SPORE Investigators Workshop(Abstract 220), 2005. e-Pub 2005.
142. Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy. 2005 AUA Annual Meeting, 2005. e-Pub 2005.
143. Tibbs RF, Abrahams NA, Wang X, Vakar-Lopez F, Pettaway CA, Pisters LL, Mathew P, McDonnell TJ, Do K, Troncoso P. Pathological characterization of residual prostate cancer in the neoadjuvant surgical model: A proposal for standardization of morphologic features of treated prostate cancer. Mod Pathol 18(1):166a, 2005. e-Pub 2005.
144. Kim J, Vakar-Lopez F, Thall PF, Wang X, Stephens CL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Pereira P, Soto C, Menter DG, Lieberman R, McDonnell TJ, Lippman SC, Sabichi AL, Logothetis CJ, Troncoso P. The effects of selenium and vitamin E on apoptosis and proliferation in prostate tissue from a preprostatectomy study in patients with clinically organ-confined prostate cancer. 96th Annual AACR Meeting, 2005. e-Pub 2005.
145. Strom S, Yamamura Y, Pettaway C, Logothetis C, Troncoso P, Do K. Clinical, epidemiologic and molecular factors as predictors of time to biochemical failure among prostatectomy patients. 96th Annual AACR Meeting, 2005. e-Pub 2005.
146. Mathew P, Yang J, Kim SJ, Fidler I, Bucana C, Troncoso P, Wang X, Thall P, Logothetis C, Navone N. Inhibition of functional osteoblasts with the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate in androgen-independent prostate cancer (PCa). J Clin Oncol 22(Suppl 14s/Abstract 4625), 2004. e-Pub 2004.
147. Zurita AJ, Hajitou A, Cardo-Vila M, Troncoso P, Logothetis C, Pasqualini R, Arap W. Preclinical development of an interleukin-11 receptor-targeted pro-apoptotic peptide against advanced prostate cancer. J Clin Oncol 22(Suppl 14s/Abstract 3190), 2004. e-Pub 2004.
148. Sanchez-Ortiz RF, Pettaway CA, Babaian RJ, Lloreta J, Johnston DA, Troncoso P. Racial differences in tumor volume and Gleason score in T1C prostate cancer: additional evidence for lowering the PSA threshold for biopsy in african american men. J of Urol 171(4):167, 2004. e-Pub 2004.
149. Abrahams NA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ, Troncoso P. Pathological characterization of residual prostate cancer (PC) following chemotherapy combined with hormonal ablation in the neoadjuvant surgical model. Mod Pathol 17(1), 2004. e-Pub 2004.
150. Mathew P, Sikes C, Multani A, Bucana C, Prieto V, Raymond K, Troncoso P, Logothetis C, Navone N. An androgen-receptor (AR)-negative human prostate cancer xenograft induces mouse-derived osteogenesis. 29th ESMO Congress Novartis Satelite Symposium, 2004. e-Pub 2004.
151. Kim J, Do KA, Wen S, Troncoso P, Babaian R, Pisters L, Pettaway C, Wood C, Lippman S, Logothetis C, Sabichi A, Xiao L, Zhang L, McDonnell T. A global assessment of gene expression in prostate cancer cells from patients enrolled in a phase II randomized trial of selenium and vitamin E. 12th SPORE Investigators Workshop, 2004. e-Pub 2004.
152. Abrahams N, Wang X, Do K, Pettaway C, Pisters L, McDonnell T, Logothetis C, Troncoso P. Pathological Characterization of residual prostate cancer (PC) following chemotherapy combined with hormonal ablation: a proposal for the standardization of the morphologic characteristics of treated prostate cancer in the neoadjuvant surgical model. 12th SPORE Investigators Workshop, 2004. e-Pub 2004.
153. Ochiai A, Reyes AO, Babaian RJ, Troncoso P. Risk factors for progression of prostatic cancer with seminal vesicle invasion. J of Urol 171(4):209, 2004. e-Pub 2004.
154. Zurita AJ, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Development of interleukin-11 receptor as a therapeutic target in advanced prostate cancer. Mod Pathol 17(1), 2004. e-Pub 2004.
155. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Tunstead JR, Troncoso P, Ruggeri A, Tu SM, Lin SH. Up-regulation of soluble ErbB3 in metastatic prostate cancer cells and activated osteoblasts in bone marrow. Mod Pathol 17(1), 2004. e-Pub 2004.
156. Sanchez-Ortiz RF, Pettaway CA, Babaian RJ, Lloreta J, Johnson DA, Troncoso P. Racial differences in tumor volume and gleason score in T1c prostate cancer: additional evidence for lowering the PSA threshold for biopsy in african american me. Mod Pathol 17(1), 2004. e-Pub 2004.
157. Ayala AG, Tibbs RF, Tamboli P, Troncoso P. High-grade prostatic intraepithelial neoplasia (PIN) like lesions: a possible embryologic remnant mimicking carcinoma. Mod Pathol 17(1), 2004. e-Pub 2004.
158. Tamboli P, Abrahams NA, Troncoso P. High grade prostatic intraepithelial neoplasia (HGPIN) in neele biopsy (NBx): Does routine use of recuts help in detecting prostate adenocarcinoma (PCa). Mod Pathol 16(1), 2003. e-Pub 2003.
159. Song R, Sanchez-Ortiz RF, Troncoso P, Johnston DA, Strom SS, Pettaway CA. The ratio of matrix metalloproteinase to e-cadherin expression in prostatectomy specimens level distinguishes organ-confined from advanced prostate cancer in african american men. Proc 94th Annual AACR Meeting, 2003. e-Pub 2003.
160. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Spitz MR, Yamamura Y. Androgen receptor CAG polymorphism and prostate cancer progression among prostatectomy patients. Proc 94th Annual AACR Meeting, 2003. e-Pub 2003.
161. Mintz P, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Proc 94th Annual AACR Meeting, 2003. e-Pub 2003.
162. Kim J, Troncoso P, Thall PF, Wang X, Llansa ND, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Johnson K, Taylor R, Menter DG, Lippman SM, Logothetis CG, Lieberman R, Sabichi AL. Effects of vitamin E and selenium on plasma lipid peroxidation: preliminary results from a randomized controlled trial of selenium and vitamin E in preprostatectomy patients. Proc 94th Annual AACR Meeting, 2003. e-Pub 2003.
163. Yamamura Y, Dahlstrom K, Qiao Y, Babaian RJ, Troncoso P, Wei Q, Spitz MR, Strom SS. Association of CYP17 and prostate cancer prognostic characteristics. Proc 94th Annual AACR Meeting, 2003. e-Pub 2003.
164. Sakr W, Grignon J, Srigley J, Troncoso P, Tamboli P, Lopez-Corona E, Reuter V. Recent trends regarding the significance of isolated high grade prostatic intraepithelial neoplasia "HGPIN" in predicting prostate cancer diagnosis? A multi-institutional study. Mod Pathol 16(1), 2003. e-Pub 2003.
165. Zurita AJ, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. A ligand peptide with potential for targeting prostate cancer metastatic to bone marrow. The University of Texas M. D. Anderson Cancer Center, 2003. e-Pub 2003.
166. Zurita AJ, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. A ligand peptide with potential for targeting prostate cancer metastatic to bone marrow. 11th SPORE Investigator's Workshop, 2003. e-Pub 2003.
167. Sanchez-Ortiz RF, Yamamura Y, Frazier ML, Babaian RJ, Troncoso P, Pettaway CA, Strom SS. Relationship between cyclin D1 polymorphism and age at diagnosis in prostate carcinoma. Proc 94th Annual AACR Meeting, 2003. e-Pub 2003.
168. Tu, SM, Reyes AO, Fanning T, Troncoso P, Bast RC, Logothetis CJ. Advanced prostate carcinoma and elevated serum CA-125 level. Proc Am Soc Clin Oncol 21(Abstract 2445), 2002. e-Pub 2002.
169. Pisters LL, McDonnell TJ, Troncoso P, Brisbay S, Hossan E, Pettaway C, Wood C, Evans R, Steiner M, Merritt J, Logothetis C. Intraprostatic Ad-p53 Gene Therapy Induces Apoptosis in Locally Advanced Adenocarcinoma of the Prostate. Proc Am Soc Clin Oncol 20(Abstract 699), 2001. e-Pub 2001.
170. Daliani D, Logothetis C, Pettaway C, Meyers C, Pisters L, Coursen C, Davies K, Troncoso P, Reyes A. TNP-470 Therapy Preceding Radical Prostatectomy (RP): A Model for Assessment of Safety and Biologic Activity of Angiogenesis Inhibitors. Proc Am Soc Clin Oncol 19(Abstract 1486), 2000. e-Pub 2000.
171. TU S, Ruiz C, Logothetis C, Troncoso P. Prostate Carcinoma Manifesting as Primary Bladder Carcinoma (Meeting Abstract). 1999 ASCO Annual Meeting(Abstract 1365), 1999. e-Pub 1999.
172. Pisters L, Pettaway C, Troncoso P, Finn L, Slaton J, Logothetis C. Preoperative Chemotherapy (CHT) and Hormonal Therapy (AA) Followed by Radical Prostatectomy (RP) for Locally Advanced Prostate Cancer (PCA) (Meeting abstract). 1999 ASCO Annual Meeting(Abstract 1212), 1999. e-Pub 1999.
173. Logothetis C, Hossan E, Evans R, Pettaway C, Steiner M, Gingrich J, Wood C, Troncoso P, Timothy M, Proksch S, Doerksen L, Merritt J, Fenstenmacher M, Pisters L. Ad5CMV-p53 Intraprostatic Gene Therapy Preceding Radical Prostatectomy (RP): An In Vivo Model for Targeted Therapy Development (Meeting Abstract). 1999 ASCO Annual Meeting(Abstract 1203), 1999. e-Pub 1999.

Book Chapters

1. McDonnell, TJ, Troncoso, P, Brisbay, S, Chung, LW, Logothetis, C, Hsieh, JT, Cambell, M, Tu, S. BCL-2 expression in the prostate and its association with androgen-independent prostate cancer, 179-185, 2024.
2. Chen ME, Johnston D, Troncoso P. Detailed Mapping of Prostate Cancer: Implications for Brachytherapy. In: Basic and Advanced Techniques in Prostate Brachytherapy. Taylor and Francis Group, 25-32, 2005.
3. Navone NM, Olive M, Troncoso P. Isolation and Culture of Prostate Cancer Cell Lines. In: Methods Mol Med. Human Press, Inc, 121-132, 2004.
4. Fidler IJ, Kuniyasu H, Greene GF, Troncoso P, and Pettaway CA. Molecular Diagnosis to Predict the Metastatic Potential of Human Prostate Cancer. In: Progress in Anti-Cancer Chemotherapy. Springer, 153-161, 2000.
5. Ayala AG, Troncoso P, Ro JY. Prostate Gland. In: The Pathology of Incipient Neoplasia. W.B. Saunders Co, 363-383, 1992.
6. Sahin AA, Ro JY, Troncoso P, Ayala AG. Benign Prostatic Lesions with Small-Acinar Pattern Mimicking Adenocarcinoma. In: Progress in Reproductive and Urinary Tract Pathology. Field and Wood, 69-86, 1990.
7. Troncoso P, Riddell RH. The Pathology of Esophageal Carcinoma. In: Carcinoma of the Esophagus. Grune and Stratton, Inc, 89-118, 1985.

Letters to the Editor

1. Bostwick DG, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, Humphrey P, Grignon D, Jones ED, McNeal J, Montironi R, Qian J, Ro J, Srigley J, Tetu B, Troncoso P, True L, Wheeler T, Young RG. Consensus statement on terminology: recommendation to use aytpical adenomatous hyperplasia in place of adenosis of the prostate. AJSP 18: 1069-1070, 1994.
2. Bostwick DG, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, Humphrey P, Grignon D, Jones EC, McNeal J, Montironi R, Qian J, Ro J, Srigley J, Tetu B, Troncoso P, True L, Wheeler T, Young RH. Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Hum Pathol 25: 840, 1994.